 
 
 
Symplicity AF C linical Investigat ion Plan 
Vers ion 18.0  
19Aug2020  
 
[STUDY_ID_REMOVED] 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 1 of 92    
 
 
 
 
 
 
 
 
Symplicity  AF 
 
Clinical Investigation  Plan  
Version  18 
19AUG 2020  
 
 
 
 
 
 
Regional S ponsors and Contacts  
United States  
Medtroni c, Inc. 
8200  Coral Sea Street NE 
Mounds  View, MN U.S.A. 55112 
1-800-328-2518 
 
Europe, Middle East, Africa  
Medtronic, Bakken Research Center B.V.  
Endepolsdomein 5  
6229 GW Maastricht  
The Netherlands  
(+31) -43-35-66-566  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 2 of 92   TABLE OF  CONTENTS  
TABLE OF  CONTENTS  ................................ ................................ ................................ .... 2 
CORE  LABS  ................................ ................................ ................................ .....................  5 
COMMITTEES  ................................ ................................ ................................ ..................  6 
1. INTRODUCTION  ................................ ................................ ................................ ..... 7 
1.1 Study  purpose  ................................ ................................ ................................ ........  7 
1.2 Study  descri ption  ................................ ................................ ................................ ... 7 
2. BACKGROUND AND  JUSTIFICATION  ................................ ................................ .. 8 
3. SYSTEM DESCRIPTION AND INTENDED  USE ................................ ...................  11 
3.1 Symplicity Spyral Renal Denervation  System  ................................ ....................  12 
3.2 Reveal LINQ ICM  System  ................................ ................................ .....................  13 
3.3 Additional system  components  ................................ ................................ ..........  13 
4. REGULATORY  COMPLIANCE  ................................ ................................ ..............  14 
5. METHODOLOGY  ................................ ................................ ................................ .. 15 
5.1 Study  objectiv es................................ ................................ ................................ ... 15 
5.2 Subject selection  criteria  ................................ ................................ .....................  15 
5.3 Minimization of  bias ................................ ................................ .............................  17 
6. STUDY  PROCEDURES  ................................ ................................ .........................  17 
6.1 Investigator/center selection  criteria  ................................ ................................ .. 17 
6.2 Center  activation  ................................ ................................ ................................ .. 18 
6.3 Equipment  requirements  ................................ ................................ .....................  18 
6.4 Role of the sponsor representative during study procedures  and follow up  
visits  19 
6.5 Data collection  ................................ ................................ ................................ ..... 19 
6.6 Patient informed consent  process  ................................ ................................ ...... 23 
6.7 Medications  ................................ ................................ ................................ ..........  24 
6.8 Enrollment and  baseline  ................................ ................................ ......................  25 
6.9 Randomization  ................................ ................................ ................................ ..... 26 
6.10  Pulmonary vein isolation procedure  ................................ ..........................  27 
6.11  Peri – procedural  anticoagulation  ................................ ...............................  28 
6.12  Renal  angiography  ................................ ................................ .......................  28 
6.13  Renal artery denervation  procedure  ................................ ...........................  29 
6.14  LINQ  insertion  ................................ ................................ ..............................  29 
6.15  Device deficiencies  ................................ ................................ ......................  30 
6.16  Hospital discharge  ................................ ................................ .......................  30 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 3 of 92   6.17  Scheduled follow -up visit  windows  ................................ ............................  30 
6.18  Scheduled in -office follow -up visits  ................................ ...........................  31 
6.19  Unscheduled follow -up visits  ................................ ................................ ...... 33 
6.20  System modification for Reveal  LINQ  ................................ ........................  33 
6.21  Permissible repeat  ablation  ................................ ................................ ........  33 
6.22  Repeat renal artery  denervations ................................ ................................  34 
6.23  Recurrence of atrial  fibrillation  ................................ ................................ ... 34 
6.24  Study  exit ................................ ................................ ................................ ...... 34 
7. INVESTIGATIONAL DEVICE STORAGE, HANDLING  AND  TRACEABILITY  ....... 35 
7.1 Symplicity Spyral Renal Denervation  System  ................................ ....................  35 
7.2 Arctic Front Advance and Freezor MAX  Cardiac Cryoablation  Catheters  ....... 36 
7.3 Final product  disposition  ................................ ................................ ....................  36 
8. STUDY  DEVIATIONS  ................................ ................................ .............................  37 
9. ADVERSE  EVENTS AND DEVICE DEFICIENCIES  ................................ ..............  37 
9.1 Adverse event  and device deficiency definitions  ................................ ..............  38 
9.2 Adverse event  and device deficiency assessment  ................................ ..........  41 
9.3 Market -released reporting  requirements  ................................ ............................  42 
9.4 Adverse event and reporting  requirements  ................................ .......................  42 
9.5 Subject  death  ................................ ................................ ................................ ....... 44 
9.6 CEC  review  ................................ ................................ ................................ ...........  45 
9.7 Adverse event  classification  ................................ ................................ ...............  45 
10. RISK  ANALYSIS  ................................ ................................ ................................ .... 47 
10.1  Risk minimi zation  ................................ ................................ ........................  50 
10.2  Potential  benefits  ................................ ................................ .........................  51 
11. PLANNED STUDY CLOSURE, EARLY TERMINATION  OF STUDY OR STUDY  
SUSPENSION  ................................ ................................ ................................ ....... 51 
11.1  Planned study  closure  ................................ ................................ .................  51 
11.2  Early termination or  suspension  ................................ ................................ . 51 
11.3  Procedures for termination or  suspension  ................................ ................  52 
12. STATISTICAL METHODS AND DATA  ANALYSIS  ................................ ..................  53 
12.1  Sample size  determination  ................................ ................................ ..........  53 
12.2  General  considerations  ................................ ................................ ...............  53 
12.3  Primary safety  objective  ................................ ................................ ..............  54 
12.4  Primary effectiveness  objective  ................................ ................................ .. 57 
12.5  Secondary  objective  ................................ ................................ ....................  59 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 4 of 92   12.6  Ancillary  objectives  ................................ ................................ .....................  60 
12.7  Subgroup  analysis  ................................ ................................ .......................  60 
12.8  Inter im analysis  ................................ ................................ ............................  60 
12.9  Pooling of study centers for analysis  ................................ .........................  61 
12.10  Missing  data ................................ ................................ ................................ . 61 
13. DATA AND QUALITY  MANAGEMENT  ................................ ................................ .. 62 
14. WARRANTY/INSURANCE  INFORMATION  ................................ ...........................  62 
15. MONITORING ................................ ................................ ................................ ........  62 
15.1  Monitoring  visits  ................................ ................................ ..........................  63 
16. REQUIRED RECORDS AND  REPORTS  ................................ ...............................  63 
16.1  Investigator  records  ................................ ................................ ....................  63 
16.2  Investigator  reports  ................................ ................................ .....................  64 
16.3  Sponsor  records  ................................ ................................ ..........................  65 
16.4  Sponsor  reports  ................................ ................................ ...........................  66 
APPENDIX A: DRAFT DATA COLLECTION  ELEMENTS  ................................ ...............  68 
APPENDIX B: PRELIMINARY PUBLICATION  PLAN  ................................ .....................  69 
APPENDIX C: DATA MONITORING  COMMITTEE  ................................ .........................  71 
APPENDIX D: INFORMED CONSENT  TEMPLATES  ................................ .....................  72 
APPENDIX E: PARTICIPATING INVESTIGATORS, INSTITUTIONS AND  IRB/MECS  .... 73 
APPENDIX F:  LABELING  ................................ ................................ ..............................  74 
APPENDIX G: BLOOD PRESSURE  MEASUREMENT  PROCEDURES  ........................  75 
APPENDIX H: BIBLIOGRAPHY AND PRECLINICAL  AND  CLINICAL  INVESTIGATIONS
 ................................ ................................ ................................ ..............................  77 
APPENDIX I: MODIFICATIONS TO THE CLINICAL  INVESTIGATION  PLAN  ................  78 
 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 5 of 92   SPONSOR CONTACT  INFORMATION  
Medtronic contact information is provided below. This information is subject to  change 
during the course of the clinical study. Periodic updates to study contact information  will 
be sent to the centers as  needed.  
 
Table 1: Study sponsor contact  information  
 
Study sponsors and  contacts  
Worldwide Clinical study  leader   Europe, Middle East, Africa (EMEA)  
Marina Ostanniy , Pr. Clinical Research  Specialist  Anita van Wijlick MSc , Sr. Clinical Research Specialist  
Di Direct Phone:  +17635269751  Direct Phone: +31 (0)6 22592645  
 anita.wijlick@medtronic.com  
marina.ostanniy@medtronic.com  
  
 Monitoring contact  
 Worldwide Monitoring  leader  
 
Beth A. Ornell, MS, Clinical Monitoring  Manager  
Direct Phone: +1 763 -280-2332  
beth.a.ornell@medtronic.com  
 
 
CORE  LABS  
Table 2: Study Core Labs  
Core Lab  Contact  information   Purpose   
VasCore  One Bowdoin Square 10th Floor  
Boston, MA 02114  
Phone: 617 -726-5552  Assessment of Renal Duplex 
Ultrasound (RDUS)  
Beth Israel  Deaconess 
Medical Center  375 Longwood Avenue, 3rd Floor  
Boston, MA 02215  
Phone: 617 -667-7000  Assessment of renal angiogram  for 
renal stenosis  
Intelemage / 
Medidata  700 W. Pete Rose Way  
Cincinnati , OH 45203  
Phone: 973 -659-6780  Study specific image uploading and 
viewing platform  
 
 
 
 
 
 
 
 
 
 
 
 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 6 of 92   COMMITTEES  
Table 3: Committee contact  information  
 
Committee  Member  Contact  information   Purpose   
Steering Committee  
Larry Chinitz,  MD 
Principal  Investigator  New York University, Langone  Medical 
Center  
333 East 30th Street 
New York, NY  10016  Provide consultation on  therapy 
and product usage throughout  the 
lifecycle of the clinical  study.  
Clinical Events  Committee  
(CEC)  Provided under separate cover, if  requested.  Provide unbiased review  of 
adverse events and adjudicate  all 
death and endpoint  events.  
Data  Monitoring 
Committee  (DMC)  Provided under separate cover, if  requested.  Provide unbiased review of  safety 
data and  provide 
recommendations for  study 
continuation or  termination.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 7 of 92   1. INTRODUCTION  
1.1 Study  purpose  
Medtronic, Inc. is sponsoring the Symplicity AF study, a prospective,  
randomized, multi -center  clinical study. This is  an investigational , feasibility  
study  in the United States ; the study is a post-market interventional study in 
Europe . The purpose of this  clinical  study is to evaluate the feasibility of 
performing both renal artery denervation  and pulmonary vein isolation on the 
same patient with the intent of characterizing  both safety and effectiveness in a 
paroxysmal and persistent atrial fibrillation  (AF) population with hypertension. 
To assess safety, a primary objective will  measure the occurrence of a 
composite safet y endpoint and, to assess effectiveness,  a primary objective will 
measure freedom of chronic treatment failure through  a minimum of six months 
of follow -up. The Arctic Front  Advance™  Cardiac Cryoablation system and  
Symplicity™ Spyral Renal  Denervation  system (Symplicity Spyral ™ Multi -
Electrode Renal Denervation Catheter and the Symplicity  G3™ Renal 
Denervation RF Generator, hereafter referred to as the Symplicity  Spyral  
Catheter and Symplicity G3 Generator) will be used in the study. Both are 
commercially available in Europe . The Arctic  Front  Advance Cardiac 
Cryoablation system is commercially available in the United States ; however,  is 
not approved for  the treatment of p ersistent AF  with an AF episode duration of6 
months  and longer ; therefore,  it is considered investigational in this  specific 
persistent AF  patient  population.  The components of the Symplicity Spyral 
Renal Denervation System  are investigational in the United States.  
This study has been designed to support the following  proposed  Indication for 
Use should Medtronic choose to study this  further:  
Renal denervation with the Symplicity System increases the success rate  and 
augments the  benefits of pulmonary vein isolation with the Arctic Front  Advance 
System in patients with symptomatic drug refractory paroxysmal and persistent  
AF and uncontrolled hypertension for the prevention of AF  recurrence.  
 
1.2 Study  description  
The study is expected  to be conducted at up to 12 centers located in The  
United  States  and up to three  center s in Europe . Up to 245 subjects will be 
enrolled in the study to ensure there are  70 randomized subjects. The number 
of enrollments permitted relative to the  number of subjects to be randomized is 
high since it is expected that a fair number  of subjects will not meet all 
screening criteria (rigorous blood pressure  monitoring  and renal anatomy) once 
consented. Center randomization will be capped at  50% (35) of the total 
randomized  subjects.  
Randomized study subjects will be followed for a minimum of six months, and  
then every six months thereafter until official study closure as determined by  
Medtronic and/or regulatory authority, whichever occurs first. Accordingly , the 
expected  total study duration is approximately fifty-seven  months,  representing  
approximately fifty-one months of enrollment and six months of subject  follow -up 
after the last patient has undergone the study  procedure.  
Interim analyses of the primary  effectiveness objective will take place and if 
data are deemed to sufficiently characterize th is study objective by the sponsor 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 8 of 92   at one of these analyses, enrollment may be stopped . 
 
2. BACKGROUND AND  JUSTIFICATION  
Hypertension1 and AF2 share many commonalities in demographics, prevalence,  and 
disease implications. These two diseases often co -exist and are each responsible  for 
considerable deleterious changes in morbi dity and mortality.3 By relative risk  score 
evaluation, the risk of developing AF in hypertensive patients is modest (relative  risk 
score = 1.4 to 2.1) when compared to other more serious cardiac conditions, such  as 
heart fa ilure (relative risk score = 6.1 to 17.5) and valvular heart disease (relative  risk 
score = 2.2 to 8.3).4 Yet, due to the much higher prevalence of hypertension in  the 
general population, hypertension accounts for more actua l cases of AF than  
compared  to any other risk factor.5 Approximately 25% of the United States 
population has  high blood pressure1, which makes it the primary risk factor for AF 
development in  North America.3,6 Currently hypertension is the most prevalent and 
independent risk factor  for developing AF, but it also is potentially the most modifiable 
risk factor for halting  the developm ent of  AF.2,7 
On its own hypertension is associated with several long -term maladaptive  cardiac  
adjustments, including: left ventricular cardiac hypertrophy, left atrial  enlargement, 
slowing of left and right atrial conduction velocity, and impaired ventricular  filling.4 
Nonetheless, these structural and physiological changes in the hypertensive heart  
also predispose and start the cardiac abnormalities which also he lp to initiate AF. This  
link between hypertension and AF is seen with demographic incidence rates. The  
annual  incidence of AF is approximately 19.2 per 1,000 person -years;7  however,  
when  examined in the subset of preexisting  hypertensive patients, the incidence of AF 
is about  94 per 1,000 person -years.8 Follow -up cohort studies demonstrated that  
hypertension  was present in approximately 50% of all North American patients with 
AF3,6 and that hypertension was shown to be causative to AF in about 15% of the  
patients .2 
Recently, a series of studies have demonstrated that pharmaceutical therapie s guided  
at reducing hypertension have also reduced atrial fibrillation incidence in patients  with 
hypertension, heart failure, and myocardial infarction. In particular,  pharmaceutical  
blockage of the renin -angiotensin system (by either angiotensin -convert ing enzyme 
(ACE) inhibitors or angiotensin II receptor antagonists) proved to be the most effective  
in reducing the incidence of AF.9,10,11,12 Animal studies confirmed that the duration of  
AF was decreased when treated with ACE inhibitors and concluded that the  renin - 
angiotensin pathway played a critical role in arrhythmogenic atrial  remodeling.13 
More recently, therapeutic renal denervation, which is the deliberate disruption of  the 
nerves connecting the kidneys with the central nervous system, has been shown to  
be an effective means of reducing elevated sympathetic  nervous system (SNS)  
activity, which is a common and key factor in disease states such as hypertension, 
heart  failure and atrial fibrillation. Renal denervation modulates the SNS activity by 1) 
reducing  the sympathetic control of renal function (renin rel ease, sodium excretion 
and renal  blood  flow) and 2) removing the renal afferent sympathetic contribution to 
central  blood  pressure  elevation.  
 
Renal denervation was developed as a potential treatment for hypertension based on 
prior surgical studies demonst rating reduction in blood pressure with surgical disruption 
of thoracoabdominal sympathetic nerves and surgical nephrectomy in renal failure 
patients.  Renal denervation is believed to interrupt efferent sympathetic nerves 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 9 of 92   impacting renal function as well as afferent nerves impacting feedback to the brain and 
thus systemic sympathetic tone. A series of early feasibility clinical studies 
demonstrated impact on hypertension as well as other associated disease processes 
where increased systemic sympathetic ton e is believed to be involved, such as heart 
failure, renal dysfunction, diabetes, and cardiac arrhythmias. Following the 
SYMPLICITY HTN -3 study, which raised concerns about incomplete denervation with 
the Symplicity renal  denervation system and lack of adequate control in some prior 
studies, two recent feasibility studies of renal denervation using the Symplicity Spyral  
renal denervation system and catheter have successfully addressed these issues and 
demonstrated the abil ity of this system to reduce blood pressure both in the absence 
and in the presence of antihypertensive drugs. Each of these  studies reported on 80 
subjects with combined systolic and diastolic hypertension (office systolic blood 
pressure between 150 and l ess than 180 mmHg; diastolic office pressure of 90 mmHg 
or above, and 24 -hour mean systolic pressure between 140 and less than 170 mmHg). 
The OFF -MED study enrolled subjects who had either not been treated with 
antihypertensive drugs or had these drugs dis continued for a period of time before 
randomization. The ON -MED study enrolled subjects prescribed 1, 2, or 3, 
antihypertensive medications.   
 
The SPYRAL OFF -MED study14 demonstrated 3 -month reductions in both office 
systolic blood pressure reduction ( -7.7-mm Hg; P = .016) and mean 24 -hour systolic 
pressure (-5.5 mmHg (p=0.04). There were no major safety events in either arm.  
Significant reductions were also observed between groups for multiple parameters 
including office diastolic blood pressure and 24 -hr mean diastolic blood pressure. This 
trial provided biological proof of principle for the efficacy of catheter -based renal 
denervation to reduce blood pressure in patients with hypertension not treated with 
antihypertensive medications, addressing the lim itations identified from the prior 
SYMPLICITY HTN -3 study.  
The SPYRAL ON -MED study15 demonstrated 6 -month placebo subtracted reductions in 
both office systolic pressure ( -6.8 mmHg; p=0.02) and mean 24 -hour systolic pressure 
(-7.4; -p=0.005) in the presence  of commonly used antihypertensive medications.  
Significant reductions were also observed between groups for multiple parameters 
including office diastolic blood pressure, 24 -hr mean diastolic blood pressure, daytime 
systolic blood pressure and nighttime systolic blood pressure. Examination of the 
circadian 24 -hr blood pressure normalized to waking time indicated that blood pressure 
reductions were consistent throughout the day and night including the high -risk 
“morning surge” period. Thus, the effects of renal denervation may provide additional 
clinical benefit during the high -risk period unlike drug therapy. The extent of blood 
pressure reduction grew during follow up, raising the possibility that further reduction 
may be seen with more prolonged follow -up. No major adverse events out to 6 months 
were reported.   
 
In order to test the hypothesis in the SPYRAL PIVOTAL - SPYRAL HTN -OFF MED 
study that renal denervation decreases blood pressure and is safe when studied in the 
absence of antihypertensive medications, study subjects were randomized to the 
Denervation or C ontrol group in a 1:1 fashion. In addition to subjects being blinded to 
their randomization assignment, site personnel involved in the measurement of office 
blood pressure were also blinded to study subjects’ randomization assignment through 
the primary en dpoint to prevent potential bias of results. Subjects were studied in the 
absence of antihypertensive medications to assess the impact of renal denervation on 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 10 of 92   systolic blood pressure in the absence of medication.  
 
Study enrollment was stopped for efficacy  after the first interim analysis in February 
2020. Data from the initial 80 patients with 3 months follow up from the SPYRAL HTN -
OFF MED study  was combined with data from the initial 251 patients with 3 months 
follow up from the SPYRAL PIVOTAL -SPYRAL HTN -OFF MED study and was 
presented at ACC World Congress of Cardiology in March 2020.   Concurrently, an 
article presenting the data was published in the Lancet.   A brief summary of the 
SPYRAL PIVOTAL -SPYRAL HTN -OFF MED data is provided below.  
 
The primary en dpoint, change in 24 -h blood pressure at 3 months, was compared 
between groups. Drug surveillance was done to ensure patient compliance with 
absence of antihypertensive medication. The primary analysis was done in the 
intention -to-treat population. Safety events were assessed to 3 months.  
 
From June 25, 2015, to Oct 15, 2019, 1519 patients were enrolled, of whom 1188 were 
excluded because they did not meet inclusion criteria. 166 were randomly assigned to 
renal denervation and 165 to the sham procedure (80 were included in the pilot and 251 
in Pivotal).  
 
There were no major safety events reported at 1 month. There was one major safety 
event in each treatment group up to 3 months (one admission to hospital for 
hypertensive crisis or emergency in  the renal denervation group and one new stroke in 
the sham procedure group), and neither was attributed to the device or trial procedures.  
 
For the primary efficacy endpoint of changes from baseline in 24 -h systolic blood 
pressure at 3 months, there was a  significant difference between the renal denervation 
and sham procedure groups. This endpoint was met with a posterior probability of 
superiority greater than 0.999 and a treatment difference of -3.9 mm Hg (95% BCI -6.2 
to -1.6). For the secondary efficac y endpoint of difference in 3 -month changes in office 
systolic blood pressure between the two groups, the difference was significant and the 
endpoint was met (difference -6.5 mm Hg (95% BCI -9.6 to -3.5), with posterior 
probability of superiority of more t han 0.999 . The blood pressure changes analysed 
using the prespecified ANCOVA -adjusted frequentist analysis of the overall population 
show similar changes in blood pressure to Bayesian results.  
 
A small pilot study in hypertensive patients with paroxysmal a nd persistent  AF 
demonstrated the benefits of concomitant AF ablation and renal denervation  (RDN) 
ablation .16   When patients were given both simultaneous AF and RDN ablation, 69%  
of the subjects were AF -free at twelve -month  post-ablation follow -up examina tion. 
This was compared to 29% of subjects that remained AF -free during the same study 
when  they were only administered an AF ablation. The 40% difference in success rate  
was attributed to the differential success that is achieved when hypertension is  
controlled  through sympathetic modulation and no longer adversely contributing to the  
disease progression of AF; in addition, direct effects on the atria following renal 
denervation  are possible.   
 
Until very recently, the treatment of AF h ad been focused on maintenance  and 
regulation of rate, rhythm, and anti -coagulation. The current therapies largely ignore  
the underlying disease process including the sympathetic nervous system’s 
involvement  into the development of hypertension and structu ral heart disease which 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 11 of 92   can lead to  the development of AF through atrial remodeling and subsequent 
maladaptive changes  in atrial electrical conduction. Aggressive treatment of 
hypertension may reverse  structural  heart changes, reduce thromboembolic events,  
and retard/prevent A F. Patients  with both paroxysmal and persistent AF are included 
in this study to better understand  the treatment effect of renal artery denervation in 
combination with cryoablation along  the AF disease continuum. In addition, this stud y 
will gather feasibility outcomes data on  the use of the Arctic Front Advance  and Arctic 
Front Advance Pro  Cardiac Cryoablation Catheter for pulmonary  vein isolation in the 
persistent AF  population.  In June 2020,  FDA granted approval of Arctic Front 
Advance, Arctic Front Pro and Freezor MAX with the Persistent AF expanded 
indication for the treatment of drug refractory recurrent symptomatic paroxysmal and 
persistent atrial fibrillation (episode duration less than 6 months).  
 
 
3. SYSTEM DESCRIPTION AND INTENDED  USE 
The study will be conducted using the components described in the table  below  (and 
future commercially released generations) . Instructions for use of the devices used in 
this study are provided in their  respective manuals.  In Europe, centers will utilize the 
commercially available  Symplicity Spyral Renal Denervation System, Arctic Front 
Advance Cardiac Cryoablation System and Reveal LINQTM Insertable Cardiac 
Monitor System within intended use.  
 
Table 4: System component  informat ion 
 
Component   Model Number  Investigational / Market -
released   Manufacturer  
Symplicity SpyralTM multi -
electrode renal 
denervation catheter 
(Symplicity SpyralTM 
catheter) and  Symplicity 
G3TM renal denervation 
RF Generator (Symplicity 
G3TM generator)  IDERDN016 or IDEHTNRDN016  
(Symplicity Spyral catheter)  
IDERDN017 or IDEHTNRDN017  
(Symplicity G3 generator)  US: Investigational  
 
 
 
 Medtronic, Inc.  
RDN016  
(Symplicity Spyral catheter)  
RDN017  
(Symplicity G3 generator ) Europe:  Market -released  
 
Arctic Front Advance 
Cardiac  Cryoablation 
System  2AF234  US: Market -released for 
treatment of paroxysmal AF  
and persistent AF with an 
episode duration less than 6 
months.  
 
Investigational for treatment of 
persistent  AF with an episode 
duration over 6 months  
 
US: Investigational for 
treatment of persistent AF with 
an AF episode duration 6 
months or greater.  Medtronic 
CryoCath LP  
 2AF284  
  
 AFAPRO23  
AFAPRO28  
  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 12 of 92    2AF233  Europe: Market -released   
2AF283  
 AFAPRO23    
 AFAPRO28    
Reveal LINQ™ Insertable 
Cardiac  Monitor (ICM)  
System  LNQ11  (Reveal LINQ ICM , 
Incision/Insertion Tool ) 
2090 (Medtronic Programmer)  
9538  or PA96000  (Patient Assistant)  
24950 /24951 /24952  (MyCareLink 
Patient Monitor)  US: Market -released   
Europe:   Market -released  Medtronic, Inc . 
 
 
 
3.1 Symplicity Spyral Renal Denervation  
System  
The system consists of the  following:  
• Symplicity Spyral™ Multi -Electrode Renal Denervation  Catheter  
• Symplicity G3™ Renal Denervation RF  Generator  
• Symplicity RF Generator Component, Foot  Switch  
• Symplicity RF Generator Component, Power  Cord  
 
The Symplicity Spyral  Renal Denervation System is intended for use of 
delivering  low-level radiofrequency (RF) energy through the wall of the renal 
artery to  denervate the human  kidney.  
In Europe, the commercially available product is indicated for the treatment of 
uncontrolled hypertension.  
This system will be considered investigational in the United States for the 
duration of the clinical  study .Arctic Front Advance Cardiac Cryoablation  System  
The system consists of the  following:  
• Arctic Front Advance Cardiac Cryoablation Catheter in two balloon  sizes  
(23mm and  28mm)  
• Arctic Front Advance Pro Cardiac Cryoablation Catheter  
• Manual Retraction  Kit 
• The Freezor  MAX Cardiac Cryoablation Catheter in two curves  (55mm and  
66mm)  
• Medtronic CryoCath®  CryoConsole  
 
Approved indication in the US: The Arctic Front Advance /Arctic Front Advance Pro  
Cardiac Cryoablation Catheter s are indicated for  the treatment of drug refractory 
recurrent symptomatic paroxysmal atrial  fibrillation  or persistent AF with an AF episode 
duration less than 6 months . 
 
Approved indication in Europe: The Arctic Front Advance /Arctic Front Advance Pro  
Cardiac Cryo ablation Catheter s are indicated for the treatment of patients with atrial 
fibrillation.  
 
Approved indication in the US: The Freezor MAX Cardiac Cryoablation Catheter is 
used as an adjunctive  device in the endoc ardial treatment of paroxysmal atrial 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 13 of 92   fibrillation in conjunction with Arctic Front Advance /Arctic Front Advance Pro  Cardiac 
Cryo ablation Catheter  for the following  uses:  
• gap cryoablation to complete electrical isolation of the pulmonary  veins  
• cryoablation  of focal trigger sites,  and 
• creation of atrial flutter line between the inferior vena cava and the  tricuspid 
valve  
 
Approved indication in Europe: The Freezor MAX  Cardiac Cryo ablation Catheter is 
intended for use in treatment of cardiac arrhythmias.  
 
This system is considered investigational for use in the persistent AF  population  with an 
episode duration over 6 months  in the United States . 
 
3.2 Reveal LINQ ICM  System  
The system consists of the  following:  
• Reveal LINQ  ICM 
• Incision  Tool 
• Insertion  Tool 
• Medtronic CareLink Model 2090 programmer or CareLink Encore  Model  
22901  programmer  
• MyCareLink® Home  Monitor  
• Reveal Patient  Assistant  
 
Approved indication in the US: The Reveal LINQ ICM is a n implantable patient - 
activated and automatically -activated monitoring system that records subcutaneous 
ECG and is indicated in the following cases:   
• Patients with clinical syndromes or situations at increased risk of  cardiac  
arrhythmias  
• Patients who experience transient sympt oms such as dizziness,  palpitation,  
syncope, and chest pain that may suggest a cardiac  arrhythmia  
 
Approved indication in Europe: The Reveal LINQ Insertable Cardiac Monitor is an 
implantable patient -activated and automatically -activated monitoring system t hat 
records subcutaneous ECG and is indicated in the following cases:  
• Patients with clinical syndromes or situations at increased risk of cardiac 
arrhythmias  
• Patients who experience transient symptoms that may suggest a cardiac 
arrhythmia  
 
This device will be used to identify recurrent AF which is further described  in Section 
12: Statistical metho ds and data  analysis . 
The AF detection algorithm looks at incoherence patterns in a series of  RR intervals 
over a period of 2 minutes to detect  AF. 
 
3.3 Additional system  components  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 14 of 92   Additional components that may be used include Medtronic FlexCath™  sheaths  and 
Medtronic Achieve ™ and Achieve Advance™  mapping catheters. Medtronic may 
incorporate  additional  components into this clinical study as they receive appropriate 
license or  regulatory  approval and are released commercially by  Medtronic.  
 
4. REGULATO RY COMPLIANCE  
The Symplicity AF clinical study is an Investigational Device Exemption (IDE)  study  
in the United States and a post -market interventional study in Europe . This clinical 
study is required to be in compliance with the CIP, Clinical Trial  Agreem ent (CTA) 
and applicable  regulations.  
This study will be conducted in compliance with ethical and scientific quality  
standards, known as good clinical practice (GCP). GCP includes review and approval 
by an independent Institutional Review Board (IRB) /Medical Ethics Committee (MEC)  
before initiating a study, continuing  review of an ongoing study by an IRB /MEC and  
obtaining and documenting the freely given  informed  consent of a subject before 
initiating the  study.  
 
The study will be conducted according to federal, national and local laws, regulations, 
standards, and  requirements of the countries/geographies where the study is being 
conducted. For all geographies, the principles of  the Declaration of Helsinki have been 
implemented through the pa tient informed consent ( PIC) process,  Ethics 
Board/IRB/MEC approval, study training, clinical trial registration, preclinical testing, 
risk-benefit assessment and publication policy.  
 
Ultimately, all centers in all geographies will follow and comply with:  
• Principles of Declaration of Helsinki (including privacy and data protection laws), or 
the laws and  regulations of each participating country, whichever affords greater 
protection for the study  subjects  
• 21 CFR Part 11 (Electronic Records, Electronic Si gnatures)  
• 21 CFR Part 54 (Financial Disclosure by Clinical Investigators)  
• The procedures described with in this CIP  
• Local Ethics Board requirements  
 
In addition to the regulatory requirements outlined above, the study will be conducted in 
compliance with relevant local laws. These include but are not limited to:  
• In the United States, US FDA 21 CFR Parts  
• 50: Protection of Human subjects  
• 56: Institutional Review Boards  
• 812: Investigational  Device Exemptions  
• In Europe, Declaration of Helsinki 2013  and the local laws  
 
All participating geographies will make study data available to the regulatory body such 
as FDA or competent authority if the regulatory body deems an onsite inspection 
necessary. The regulatory body will be able to inspec t records at clinical centers around 
the world to resolve any uncertainties about whether the study was conducted in 
accordance with good clinical practice.  
The study will be publicly registered prior to first enrollment in accordance with the  2007  
Food an d Drug Administration Amendments Act (FDAAA) and Declaration of Helsinki  
on http://clinicaltrials.gov.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 15 of 92   Approval of the CIP, CIP revisions or CIP amendments is required from the  following  
groups prior to any stu dy procedures at a study center: Medtronic, FDA, regulatory  
body, Principal Investigators (where required by law ), and an IRB /MEC  at each study  
center.  
Similarly, approval of subsequent revisions to the CIP is required at each study 
center from the above -mentioned  groups prior to implementation of the revised CIP 
at the center.  
 
5. METHODOLOGY  
5.1 Study  objectives  
There are two primary objectives, one secondary objective, and six  ancillary 
objectives for this study. The primary safety objective compares the rate of  
safety  composite events between subjects randomized to receive both 
pulmonary  vein isolation and renal artery denervation within one procedure 
compare d to subjects randomized to receive pulmonary vein isolation alone. 
The primary  effectiveness objective compares the proportion of subjects in 
each study arm that are free  from a chronic treatment failure through all follow -
up. Further details about  study  objectives can be found in Section  12. 
 
5.2 Subject selection  criteria  
Subjects will be screened to ensure they meet all the inclusion and none of  the 
exclusion criteria. IRB /MEC  and Medtronic approval of the Symplicity AF CIP  
and Informed Consent Form must be obtained prior to enrolling subjects in the  
study.  
Enrollment of the subject must occur prior to any study procedures take  place.  
5.2.1  Inclusion  criteria  
• Drug refractory recurrent symptomatic paroxysmal or persistent  atrial 
fibrillation  
o Drug refractory is defined as: failed (drug is ineffective,  or patient  is 
intolerant) at least one Class I or III anti -arrhythmic  drug 
o If the subject has persistent atrial fibril lation it must have  been  
diagnosed within the last two years from the date of consent with  a left 
atrial volume index ≤ 40 ml/m2 within the last year from the  date of  
consent  
• Office -based systolic blood pressure > 140 mm Hg based on average  of three 
blood pressure readings despite treatment with 1 or  more  antihypertensive 
medication (s). The subject should be on a  stable antihypertensive drug 
regimen with no changes for a minimum of 2  weeks prior to enrollment and the 
antihypertensive drug regimen is n ot expected  to change for at least 6 months, 
as determined by the subject’s  referring  cardiologist and/or the  investigator.  
• Age 18 years to 80 years  old 
• Willing to give informed consent and agree to all study procedures, and  is 
competent and willing to provide written, informed consent to participate  in this 
clinical study  
• Willing and able to be remotely monitored through the  Medtronic 
CareLink® Network  
 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 16 of 92   5.2.2  Exclusion  criteria  
• Active systemic infection  
• Cryoglobulinemia  
• One or more pulmonary vein  stents  
• Type I Diabetes  
• NYHA Class IV heart failure with in the past 6  months  
• Renal artery anatomy that is ineligible for treatment  including:  
o Lacks at least one renal artery for each kidney with ≥3 mm  and ≤ 8 mm 
diameter  and minimum treatable length per the Spyral Instructions for  
Use prior to a significant arterial branch (NOTE: All renal arteries with  ≥3 
mm and ≤ 8 mm  diameter with minimum treatable length per the  Spyral  
Instructions for Use shall be treated, including dual renal  arteries  
meeting these morphologic  criteria.)  
o Renal artery stenosis (>50%) or renal artery aneurysm in  either  
renal  artery  
o A history of prior renal artery intervention including  balloon  
angioplasty or  stenting  
o Renal artery which contain calcification which does not allow  at 
least four radio frequency ablations to be  delivered  
o Diffuse fibromuscular dysplasia (FMD) or FMD which does not  allow  at 
least four radio frequency ablations to be delivered; FMD  defined  as 
visible beading of the artery on  angiography  
o Unilateral  kidney  
• Estimated Glomerular Filtration Rate (eGFR) of <30  mL/min/1.73m2 
• Primary pulmonary  hypertension  
• Pheochromocytoma, Cushing’s Disease, coarctation of the aorta,  untreated 
hyperthyroidism, primary hyperparathyroidism or hyperaldosteronism  (Note: 
treated hyperthyroidism is  permissible)  
• Myocardial infarction, unstable angina pectoris, syncope, PCI/PTCA,  or 
coronary artery stenting within 3 months prior to signing the consent  form, or 
has widespread atherosclerosis with documented  intravascular throm bosis or 
unstable  plaques  
• Cerebrovascular accident or TIA within 1 month prior to signing the  consent  
form 
• Prior ablation for atrial fibrillation in the left  atrium  
• Presence of a permanent pacemaker, biventricular pacemaker,  atrial 
defibrillator or any type of implantable cardiac defibrillator (with or  without  
biventricular pacing  function)  
• Cardiac valve stenosis for which a significant reduction of blood pressure  is 
contraindicated  
• A condition that would prohibit or interfere with a bility to obtain an  accurate blood 
pressure measurement using the protocol -specified automatic  blood  pressure 
monitor (e.g., arm diameter too large for the  cuff) 
• Serious medical condition, which may adversely affect the safety  and/or  
effectiveness of the p articipant or the trial (e.g., patients with  clinically  
significant peripheral vascular disease, abdominal aortic  aneurysm, 
bleeding disorders such as thrombocytopenia, hemophilia, or  significant 
anemia)  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 17 of 92   • Pregnant, nursing or planning to be pregnant. [Female participants  of 
childbearing potential must have a negative serum or urine  human  
chorionic gonadotropin (hCG) pregnancy test prior to  angiography]  
• Known history of drug use or alcohol dependency, lacks the ability  to 
comprehend or follow instructions, or would be unlikely or unable to  comply 
with study follow -up requirements  
• Previous organ  transplant  
• Currently enrolled or plans to participate in a potentially confounding  drug or 
device trial during the course of this study. Co -enrollment i n concurrent 
studies is allowed when documented pre -approval is obtained from  the 
Medtronic study  manager.  
 
5.3 Minimization of  bias 
Selection of subjects, treatment of subjects, and evaluation of study data  are potential 
sources of bias. Methods incorporated in the study design to  minimize potential bias 
include (but are not limited  to): 
• Subjects will undergo a rigorous screening to confirm eligibility  for 
enrollment with defined inclusion/exclusion criteria prior to  enrollment  
• All centers will us e the same version of the CIP and Case Report  Form 
(CRFs)  
• Data collection requirements and study procedures will be standardized  for all 
centers  
• All investigational center personnel and Medtronic personnel will be  
trained  on their respective aspects of the study using standardized  
training  materials  
• All investigational center personnel will be trained on and required to  
follow  the CIP  
• An independent CEC will be utilized to regularly review and  
adjudicate reported adverse events and  deaths  
• An independent DMC will be utilized to safeguard the interests of  
study  subjects and monitor the overall conduct of the  study.  
In summary, potential sources of bias that may be encountered in this  clinical  
study have been considered and minimized by careful study  design.  
 
6. STUDY  PROCEDURES  
6.1 Investigator/center selection  criteria  
An Investigator/center may be included in this investigation if they meet  the 
following  criteria:  
• Principal Investigator is credentialed in catheter ablation and  femoral  
arterial cannulation in a hospital with an interventional vascular  
specialist who is credentialed in renal artery interventions.  The 
vascular  specialist is to be immediately on -call during the renal 
denervation procedure  to assist as needed in renal artery cannula tion, 
catheter manipulation  within the renal artery, and managing any 
vascular adverse events such  as renal artery perforation or  dissection.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 18 of 92   • Principal investigator has experience using the Arctic Front® / 
Arctic Front Advance /Arctic Front Advance Pro  Cardiac 
Cryoablation Catheter system in at least  10 cases.  
• Center has a Medtronic CryoCath CryoConsole installed at the  
facility (Generation 5  console).  
• Willingness to perform both pulmonary vein isolation ablation with  the 
Arctic Front Advance /Arctic Fro nt Advance Pro  Cardiac Cryoablation 
Catheter system and  renal  artery denervation with the Symplicity 
Spyral Catheter and Symplicity  G3 Generator during the same  case.  
• Principal investigator has access to an adequate number of  
potential  subjects.  
• Sufficient experienced staff and equipment (e.g. study coordinator,  
renal  duplex ultrasound, renal angiography, and trans -thoracic  
echocardiogram (TTE)) to execute and maintain protocol  compliance.  
 
6.2 Center  activation  
During the activation process (prior to  subject enrollment), Medtronic will  train 
center personnel on the CIP, relevant standards and regulations,  informed 
consent, data collection and reporting tools. If new members join  the 
investigational center team, they will receive training on the applic able clinical  
study requirements relevant to their role before contributing to the clinical  study.  
Prior to performing study related activities, all local regulatory requirements  
shall be fulfilled, including, but not limited to the  following:  
• Medtronic and IRB /MEC  approval (and membership roster/voting list, as 
required by local law) of the current version of the CIP and  Informed  Consent  
Form , subject facing materials, Report of Prior Investigation as required by 
local laws and other materials, as necessary  
• Regulatory  authority  approval or  notification  (as required per local law)  
• Fully executed Clinical Trial Agreement  (CTA)  
• Investigator Curriculum Vitae  (CV) 
• Delegation of center personnel  responsibilities  
• Documentation of study  traini ng 
• Financial  Disclosure  
 
In addition, all participating center staff must be trained on the current version  of the 
CIP and must be delegated by the principal investigator to perform  study  related  
activities.  
 
Additional requirements imposed by the IRB/MEC and regulatory authority shall be 
followed.  
Medtronic will provide each study center with written documentation of  study  
center/investigator readiness, this letter must be received prior to  subject enrollment.  
Additional center personnel included after the initial activation will be notified when all 
requirements have been completed.  
 
6.3 Equipment  requirements  
The following equipment must be available at each center to support  study  activities:  
• Trans -thoracic  echo cardiogram  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 19 of 92    
 
 
 
 
 
 
 e r u d e c o r P  
 
 
 
 
 
 
 e r u d e c o r P • Renal  angiography  
• Renal duplex  ultrasound  
The maintenance and calibration of the equipment listed above will be  assessed  by 
the participating center following their normal processes. Clinical monitors  will not 
monitor maintenance or calibration  schedules.  
 
The sponsor will supply all required study  materials for appropriate data collection 
before study  start, like the office blood pressure monitors (OBPs). Medtronic will 
control the supply of devices and study materials  
 
6.4 Role of the sponsor representative during study procedures  and 
follow up  visits  
Sponsor representatives may provide support as required for the study  under  supervision 
of the Principal Investigator,  including:  
• Provide study training relevant and pertinent to the involvement of  personnel  
conducting study activities and investigator  responsibilities  
• Technical support at the pulmonary vein isolation, renal denervation  and Reveal 
LINQ insertion procedures under the supervision of a  study  investigator, but no 
data entr y, shall be performed by Medtronic personnel  or their representatives at  
sites 
• Monitoring and auditing  activities  
• Follow up visit activities involving the Reveal LINQ device and  CareLink  
 
6.5 Data collection  
Clinical data is collected at designated time points throughout the study. Data  will be 
collected using an electronic data management system for clinical  studies.  
Data will be stored in a secure, password -protected database which will be  backed  up 
nightly. Data will be reviewed using programmed and ma nual data  checks.  
Data queries will be made available to study centers for resolution.  Study  management 
reports may be generated by Medtronic to monitor data quality  and study  progress. At 
the end of the study, the data will be frozen and  retained indefini tely by Medtronic. Data 
collection requirements are summarized in Table 5. 
 
Table 5: Data collection and study procedure requirements at subject  visits  
 
            Repeat  
cryoablation 
Procedure  (0- 
90 days),  if 
performed  
 
Enrollment/Baseline  
CT Scan  
Cryoablation 
Procedure  
Renal  Artery 
Denervation  
Reveal LINQ 
Insertion  
Hospital  Discharge  
1 month  
6 month  
Every 6  months 
until study  end 
closure 12 month  
Unscheduled  
Exit 
Baseline  
Cryoablation  
Hospital  Discharge  
Informed  Consent  x              
Inc/Exc  criteria  x x  x        x   
Medical  history  x              
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 20 of 92               Repeat  
cryoablation 
Procedure  (0- 
90 days),  if 
performed  
 
Enrollment/Baseline  
CT Scan  
Cryoablation 
Procedure  
Renal  Artery 
Denervation  
Reveal LINQ 
Insertion  
Hospital  Discharge  
1 month  
6 month  
Every 6  months 
until study  end 
closure 12 month  
Unscheduled  
Exit 
Baseline  
Cryoablation  
Hospital  Discharge  
Physical  exam  x      x x x x  x   
Trans -Thoracic 
Echocardiogram  x (1)              
Review 
medications  x     x x x x x x x  x 
Office BP  x3 x      x (8) x (8) x (8) x  x   
Blood and  urine  
labs:  Serum  
Creatinine  (sCr), 
Spot urine  
albumin  and 
creatinine  and 
Cystatin  C x     x x x  x (2)     
Review  of 
symptoms  x      x x x x     
Randomization   x             
Pregnancy  test x (3)              
Transesophageal  
Echocardiogram 
(TEE) (3)    x (4)            
Renal  angiogram  
for Treatment 
group  only    x           
Procedure 
information   x x x x        x  
CareLink  in-office 
interrogation  (5)     x (6) x x x x     
CareLink  manual  
home  
transmission        x (5)  x    
Renal Artery 
Imaging -Duplex  
Ultrasound         x 
(7)       
Adverse  Events, 
Reveal LINQ 
System  
Modification, 
Death,  Study  
Deviation,  Device 
Deficiencies   
 
 
As they  occur  
1. For subjects  with persistent  AF, perform  during  the 12 month  interval  preceding  the Consent  Date,  or 
between Consent Date and Procedure  Date.  
2. Optional, if  performed.  
3. Perform within 5 days prior to the  Procedure.  
4. TEE at baseline  to assess  for LA thrombus  as indicated  by the 2012  HRS/EHRA/ECAS  Expert 
Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation (Section  6.7). 
5. CareLink transmissions need to occur at a minimum one time per month. For the monthly  CareLink 
transmissions that coincide with a scheduled follow -up visit (i.e. 1 or 6 -month visits), a  monthly transmission  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 21 of 92   is not required  but perform  an in-office  device  interrogation  and data transfer  to Medtronic.   A CareLink 
transmission may be used as a substitute for an in -office device interrogation.  
6. Ensure a device interrogation with final programmed settings is transferred to Medtronic. This may  be at 
the time of insertion or prior to hospital  disch arge.  
7. Only for subjects  who underwent  the renal  denervation  procedure  (randomized  to the Treatment  group). If  
clinically  significant  renal  artery  stenosis  is suspected,  a follow -up renal  angiogram  will be performed.  
8. Office blood pressure (according to guidelines in Appendix G), needs to be obtained if an office visit occurs 
or during alternative methods of data collection as described in section 6.18.1.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 22 of 92    
Figure 1: Study design  flowchart  
 
 
 
 
Enrollment/Baseline 
CT scan and 
rando mization  
Pulmonary  vein 
isolation  
Control: LINQ 
insertion  
Treatment : renal 
angiogra m, renal 
artery  dener vation 
and LINQ insertion  
Hospital Discharge  
 Hospital Discharge  
1 month and 6 
month 
1 month and 6 
month 
Every 6 months  until 
study closure 
Every 6 months  until 
study closure 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 23 of 92   6.6 Patient informed consent  process  
Patient informed consent is defined as legally effective, documented  confirmation  of a 
subject’s (or their legally authorized representative or guardian)  voluntary agreement to 
participate in a particular clinical study after information has  been  given to the subject 
on all aspects of the clinical study that are relevant to  the subject’s decision to 
participate. This process includes obtaining Consent and  an Authorization to Use and 
Disclose Personal Health  Information/Research Authorization/other privacy language 
as required by law that has been  approved  by the investigational center’s IRB /MEC  
and signed and dated by the subject (or  their legally authorized representative , US 
ONLY).  A subject may only consent  after information has been given to the subject on 
all aspects of the clinical  investigation  that are relevant to the subject’s decision to  
participate.  
Prior to enrolling subject s, each investigational center’s IRB /MEC  will be required  to 
approve the Consent Form, and Authorization to Use and Disclose  Personal  Health 
Information/Research Authorization/other privacy language as required  by law. The 
document(s) must be controlled (i .e. versioned and/or dated) to ensure  it is clear which 
version(s) were approved by the IRB /MEC . Any adaptation of the  sample Consent 
Form must be reviewed by Medtronic and the IRB /MEC  reviewing  the application prior 
to enrolling subjects. Refer to Appendix D: Informed  consent  templates  for the sample 
Consent  Form.  
Prior to initiation of any study -specific procedures, patient informed consent  must be 
obtained from the subject (or their legally authorized representative  or guardian). The 
informed consent process must be conducted by the  principal  investigator or an 
authorized designee, and the Consent Form and Authorization  to Use and Disclose 
Personal Health Information/Research  Authoriz ation/other  privacy language as 
required by law must be given to the subject (or their  legally authorized representative 
or guardian) in a language he/she is able to read  and understand. The process of 
patient informed consent must not be conducted  using c oercion or undue improper 
influence on or inducement of the subject  to participate by the investigator or other 
center  personnel.  
The process of obtaining patient informed consent  shall:  
• Not waive or appear to waive subject’s legal  rights  
• Use language that  is non -technical and understandable to the  subject  
• Provide ample time for the subject to read and understand the  informed  
consent form and to ask questions, receive answers and  consider  
participation  
• Include a personally dated signature of the subject acknowledging that  their 
participation in the study is  voluntary  
 
In Europe, include a personally dated signature by the Principal Investigator or 
authorized designee responsible for conducting the informed consent process.  
 
If the Consent Form is  obtained the same day the subject begins participating  in study -
related procedures, it must be documented in the subject’s case history  that consent 
was obtained prior to participation in any study -related procedures. It  is best practice 
for the informed consent process to be documented in the  subject’s case history, 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 24 of 92   regardless of circumstance. It is also best practice to document  in the subject’s case 
history if they were re -consented for any  reason.  
In the event the subject cannot read and/or write, witnessed (impartial third  party) 
patient informed consent will be allowed, provided detailed documentation of  the 
process is recorded in the subject’s case history and the witness signs and  dates  the 
patient informed consent. In Europe, when a subj ect cannot read and/or write, an 
independent witness shall be present throughout the process, the written PIC Form and 
any other information shall be read aloud and explained to the prospective subject. The 
subject should “make his mark” (sign  or otherwise physically mark the document so as 
to indicate consent) on the  Consent  Form as well. The Consent Form should document 
the method used  for communication with the prospective subject and the specific 
means by which  the prospective subject communica ted agreement to participate in the  
study.  
The original or a copy of the signed Consent Form must be filed in  the hospital/clinical 
chart and with the subject’s study  documents.  
The Consent Form and Authorization to Use and Disclose Personal  Health 
Informa tion/Research Authorization/other privacy language as required by  law must be 
available for monitoring and auditing. Any Medtronic Field personnel  who support 
study procedures must be able to review the subject’s signed and  dated  Consent 
Form and verify it s completeness prior to proceeding with  study  procedures. In the 
event the Medtronic Field personnel identify patient  informed  consent as being 
incomplete, the study procedures will not be allowed to  occur  until the consent of the 
subject can be adequately  and appropriately  obtained.  
Any changes to a previously approved Informed Consent Form throughout  the course 
of the study must be approved by Medtronic and the IRB /MEC  reviewing  the 
application before being used to consent a prospective study subject.  The 
document(s) must be controlled (i.e. versioned and/or dated) to ensure it is  clear  which 
version(s) were approved by the IRB /MEC . All important new information  should be 
provided to new and existing subjects throughout the  study.  
 
6.7 Medications  
The colle ction of the following medications will take place during the course of  this 
study: anticoagulants, those prescribed to treat atrial fibrillation, including  those used 
for rate control, and those prescribed to treat hypertension.  Information  collected will  
include the medication name, purpose and start/stop  dates.  
 
It is recommended to maintain all randomized subjects on their  baseline  hypertensive 
medications without changes until the 6-month  visit. A study  deviation  is not required if 
changes are made to these  medications.  
If a subject is on amiodarone, it is recommended to take them off 4 -6 weeks  before the 
end of the 90-day post cryoablation procedure blanking  period.  
It is recommended that subjects be off all antiarrhythmic medications within  90 days 
post cryoablation  procedure.  
Medication changes that occur specifically because the subject will undergo  the study 
procedures should not be  recorded.  
All medications are permitted in this study with the exception of  investigational  drugs 
that may confound the study  results.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 25 of 92    
 
6.8 Enrollment and  baseline  
When a patient signs and dates the Consent Form, he/she is considered a  subject 
enrolled in the study. The date the subject signed the Consent Form  and 
Authorization to Use and Disclose Personal Health  Information/Research Authorization 
must be documented. The following evaluations will be  performed  after consent, unless 
previously performed as part of routine clinical  evaluations  within the specified  
windows:  
 
Within 12 months prior to the consen t date or between consent date and 
procedure date  
If the subject has a diagnosis of persistent AF, confirm the left atrial volume  index  is ≤ 
40 ml/m2 by a trans -thoracic  echocardiogram.  
A trans -thoracic  echocardiogram  on file can be used  providing  it is within  the last year 
from the date of consent, if not, perform a trans -thoracic  echocardiogram.  
 
After consent date but before the procedure date  
• Assessment of all factors specified for evaluation under Inclusion  Criteria and 
Exclusion Criteria (Section  5.2). 
• Medical history including: assessment of risk factors, NYHA  cardiac functional 
class, systemic history and cardiovascular history, assessment  of atrial 
fibrillation history and symptoms and other arrhythmic  episodes  
• Physical examination: height, weight, and heart rate.  
• Office blood pressure: To assess if the average of 3 office systolic  blood  
pressures measured per guidelines ( Appendix G: Blood  Pressure  
Measurement Procedures ) is > 140  mmHg.  
o If a subject’s  average  of 3 systolic  blood  pressures  is ≤ 140 
mmHg, then repeat blood pressure measures (according  to Appendix 
G: Blood Pressure Measurement Procedures ) are allowed up to two 
times over the subsequent 2 weeks.  Any subjects  with an average  
office  systolic  blood  pressure  ≤ 140 mmHg  after a total of three  
attempts  will be excluded  from the study.  
o For instructions on blood pressure measurement, see  Appendix  G: 
Blood Pressure Measurement  Procedures . 
o This will be the baseline measurement for statistical  comparison and 
inclusion  criteria  
• Laboratory testing: Subjects should be instructed to avoid eating or  drinking 
caffeine or alcohol for 10 -12 hours prior to lab testing but should drink  water  
normally (avoid other liquids) and take prescribed medications during  this time.  
o Serum cr eatinine (sCr) to calculate eGFR for eligibility  criteria  and as 
a factor of baseline kidney function. eGFR should  be calculated using 
the Modification of Diet in Renal  Disease (MDRD) Formula: eGFR 
(mL/min/1.73 m2)=175 x  (sCr/88.4) - 
1.154 x (Age) -0.203 x ( 0.742 if female) x (1.212 if of  African  descent) 
(SI units).  
o Subjects with eGFR <30 mL/min/1.73m2 will be excluded  from the  
study.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 26 of 92   o Spot urine  albumin  and creatinine  to evaluate  the albumin  to 
creatinine ratio (UACR) as a factor for baseline kidney  function.  
o Blood test: Cystatin C to help detect and monitor acute  and chronic 
kidney  dysfunction.  
• Confirm the subject has eligible renal anatomy via  computerized  
tomography (CT scan)  
• Perform randomization after eligibility has been confirmed,  see 
Section  6.9. 
 
Performed within 5 days prior to the procedure date  
• Blood or urine test -Serum or urine human chorionic gonadotropin  (hCG) 
Pregnancy test to confirm negative pregnancy status of females  of 
childbearing  potential.  
• Transes ophageal Echocardiogram  (TEE)  
Prior to undergoing an AF ablation procedure,  a TEE should be  performed in 
all subjects with atrial fibrillation more than 48 hours in duration or of  an 
unknown duration if adequate systemic anticoagulation has not  been  
mainta ined for at least 3 weeks prior to the ablation  procedure.  
 
Performance of a TEE in subjects who are in sinus rhythm at the time  of 
ablation or subjects with AF who are in AF but have been in AF for  48 hours or 
less prior to AF ablation may be considered but is not  mandatory . 
 
Subjects noted to have left atrial thrombus on TEE will not undergo  the 
procedure and will be exited from the study unless thrombus resolution  is 
confirmed on a repeat  TEE.  
 
6.9 Random ization  
Randomization schedules will be prepared for each site using a random  permuted  
block design stratified by center and AF diagnosis. The schedules will  allocate subjects 
in a 1:1 ratio to the treatment or control  arm. 
Each center will receive a set o f sequentially numbered envelopes  labeled  specifically 
for that center that is labeled with one randomization code  per envelope. After a CT 
scan has been performed and confirmed that the  renal  anatomy meets eligibility 
requirements, the subject will be  randomized.  
The next sequential envelope labeled with a randomization code will be used.  The 
envelope number will be recorded for each randomized subject and  communicated  to 
Medtronic. The sequence of subject randomization will be checked to ensure  it 
matches the sequence of envelope  numbers.  
Randomization assignments are the  following:  
• Treatment:  
o Perform the pulmonary vein isolation procedure,  renal  angiogram, 
renal artery denervation procedure and the  Reveal  LINQ  insertion.  
• Control:  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 27 of 92   o Perform the pulmonary vein isolation procedure and the  Reveal  
LINQ insertion.  Do NOT perform renal  denervation.  
 
Enrolled subjects who were not randomized should be exited. See Section  9.2.2  if 
the subject has an ongoing adverse  event.  
Subjects and center personnel will be blinded to the randomization  assignment  until 
after the pulmonary vein isolation  procedure.  
Crossing over to the Treatment group once assigned to the Control group is  not 
allowed at any point during the  study.  
 
6.10 Pulmonary vein isolation  procedure  
Perform the pulmonary vein isolation procedure first using Arctic Front  Advance /Arctic 
Front Advance Pro . Investigator is to perform the procedure according to the 
procedural steps in  this protocol and the Instructions fo r Use for the Arctic Front 
Advance /Arctic Front Advance Pro  Cardiac  Cryo ablation System. Appropriate 
systemic anticoagulation and sedation  should be attained at the investigators 
discretion according to their institutions  pre- established procedures/guidel ines at the 
time of the procedure.  Current  recommendations for anticoagulation are found in the 
2012 Expert  Consensus  Statement on the Ablation of atrial  fibrillation.17 
6.10.1  Diaphragm  Movement  
a. Phrenic nerve pacing or other phrenic nerve monitoring technique must  be 
done for each cryoapplication, specifically those  cryoapplications  surrounding 
the RS and RI pulmonary  veins  
b. Prior to the first cryoablation application, the Investigator will make  a 
fluoroscopic recording of insp iratory and expiratory movement of  the 
diaphragm  
c. After the last cryoablation application, the investigator will make  a 
fluoroscopic recording of the inspiratory and expiratory movement of  the 
diaphragm  
 
6.10.2  Balloon Pulmonary Vein (PV)  Cryoablation  
a. Every effort  consistent with subject welfare will be made to treat all PVs  or 
their anomalous  equivalents.  
b. The Arctic Front Advance /Arctic Front Advance Pro  Cardiac Cryo ablation 
Catheter will then  be advanced into the LA and inflated. Once inflated, the 
catheter will  be tracked over the wire and positioned at the entrance of the  
PV. 
c. Assess the positioning, contact and occlusion of the PV by the  catheter’s 
balloon by ultrasound imaging, injection of contrast material or  other 
technique. Reposition as  neede d. 
d. After one or more cryoapplications, each pulmonary vein should  be minimally 
assessed for entrance block and, where assessable, exit block  to demonstrate 
the cryoablation procedure endpoint of electrical isolation  of the four major  PVs.  
 
6.10.3  Gap or Touch Up  Ablation  
At the Investigator’s discretion, a focal cryocatheter or a radio  frequency catheter 
may be performed to complete electrical isolation of one or  more PVs.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 28 of 92    
6.10.4  Other  Ablations  
Subjects may have other cardiac rhythm abnormalities requiring  treatment 
detected during the ablation procedure. This may include right/left  atrial  flutter 
or atrial fibrillation triggers. Treatment of such abnormalities is at  the 
Investigator’s discretion. Such ablation will be fully documented in  the relevant  
CRF.  
 
6.10.5  Procedure  Documentation  
During the procedure the investigator will document the  following:  
a. Catheter used for each ablation (i.e. Arctic Front Advance /Arctic Front Advance 
Pro, Freezor MAX  or radiofrequency)  
b. Temperature for each  application  
c. Duration of each  application  
d. Vein location for each application (e.g. right superior pulmonary  vein)  
e. Use of phrenic nerve pacing or other phrenic nerve monitoring  technique  for 
each application, specifically those applications surrounding the RS  and RI 
pulmonary  veins  
f. Demonstrated electrical  block  
g. Adjunctive mapping or visualization devices, sedation type,  procedure 
information, fluoroscopy time, contrast dye amount and concentration  will be  
collected.  
 
6.11 Peri – procedural  anticoagulation  
Heparin should be administered prior to or immediately following  transseptal  puncture 
during AF ablation procedures and adjusted to achieve and maintain  an ACT of 300 to 
400 seconds.  
Performance of AF ablation in subjects systemically anticoagulated with  warfarin does 
not a lter the need for intravenous heparin to maintain a therapeutic  ACT during the  
procedure.  
Administration of protamine following ablation to reverse heparin may  be considered.  
 
6.12 Renal  angiography  
Perform renal angiography if randomized to Treatment, followin g the  pulmonary vein 
isolation  procedure.  
Subjects should be prepped for a renal angiography according to  standard 
procedures. For subjects with chronic kidney disease and/or risk factors  for contrast -
induced nephropathy (CIN), the hospital’s standard -of-care protocol  for CIN 
prevention should be  utilized.  
An aortogram and selective renal angiography will be performed to confirm  renal  
artery anatomy. Anatomic eligibility is defined as each kidney having at least  one 
renal artery ≥3mm  and ≤8mm  in diameter and minimum treatable length per the  
Symplicity Spyral Catheter Instructions for Use, without significant stenosis or  other  
abnormality. NOTE: All renal arteries with ≥3 mm and ≤ 8 mm  diameter with  minimum 
treatable length per the Symplicity Spyral Catheter Instructions for Use shall  be 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 29 of 92   treated, including dual renal arteries meeting these morphologic  criteria.  
 
6.13 Renal artery denervation  procedure  
If randomized to Treatment, the renal artery denervation procedure will  be performed 
according to the supplied Symplicity Spyral Catheter Instructions  for Use, Symplicity 
G3 Generator User Manual and associated training provided  by Medtronic.  
Prior to this procedure, appropriate systemic anticoagulation and sedation  should be 
attained. Blood pressure and heart rate should be closely  monitored throughout the 
procedure. Investigators may choose to apply treatment to  any renal artery that meets 
the anatomy eligibility criteria. The Symplicity  Spyral Catheter will be delivered to t he 
renal artery and the ablation treatments at  multiple positions along the renal artery will 
be performed according to the  procedures  described in the Instructions for  Use. 
Provide one copy of the renal angiogram cine procedure to  Medtronic.  
Sedation type , procedure information, fluoroscopy time, contrast dye amount  and 
concentration will be  collected.  
 
6.14 LINQ  insertion  
Before the subject is discharged from the hospital, preferable while still in the  EP lab, 
insert the Reveal LINQ device. The insertion proce dure will be performed  in 
accordance with the hospital’s standard practice and in accordance with  the Medtronic 
Reveal LINQ manual. Program Device Data Collection parameters  and verify device 
sensing performance is acceptable. Subjects with an existing  Reveal LINQ device may 
be enrolled if they have a minimum of 1 year remaining  battery life. Ensure the device 
is programmed to the settings  below.  
 
6.14.1  Programming  Requirements  
Required  programming:  
 
Parameter   Required Setting   
Reason for  Monitoring  AF ablation  
Type of AT/AF  detection  AF only 
AF Detection  Balanced  sensitivity  
AT/AF Record of ECG  of All episodes  
Ectopy  Rejection  Nominal  
 
Recommended  programming:  
 
Parameter   Required Setting   
Tachy  detection  OFF 
Brady  detection  OFF 
Pause  detection  OFF 
 
 
Perform a device interrogation and data transfer (e.g. save -to-disk, USB  data transfer) 
with the final programmed settings. Final interrogation may be  performed  at hospital 
discharge. Ensure, at a minimum, Medtronic receives an  interrogati on with the final 
programmed  settings.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 30 of 92    
6.15 Device deficiencies  
A device deficiency is defined as inadequacy of a medical device with respect  to its 
identity, quality, durability, reliability, safety or performance. NOTE:  Device deficiencies 
include malfunctions, use errors and inadequa cy in the information supplied by the 
manufacturer including  labeling.  Device deficiencies that do not adversely affect the 
subject should be reported  to Medtronic as a device deficiency and not as an adverse 
event. If the device deficiency is a reportable adverse event, the event should be 
reported as  an adverse event not a device deficiency. Report device deficiencies for all  
Medtronic products  used.  
 
6.16 Hospital  discharge  
Prior to discharge, the following shall be collec ted: blood and urine  samples, assess 
medications, assess adverse events, and review study requirements  with the subject 
to help ensure compliance with follow -up procedures.  
The use of CareLink will then be reviewed and training will be given prior  to discharge to 
the subject.  
Systemic anticoagulation with warfarin or a direct thrombin or Factor Xa inhibitor  is 
recommended for at least two months following the AF ablation  procedure.  
Decisions regarding the continuation of systemic anticoagulation agents  more  than two 
months following ablation should be based on the subject’s risk factors  for stroke and 
not on the presence of AF. Discontinuation of systemic  anticoagulation  therapy post 
ablation is not recommended in subjects who are at high risk  of stroke as estimated by 
currently recommended schemes (CHADS2  or CHA2DS2VASc).  
 
6.17 Scheduled follow -up visit windows  
After receiving notice of a subject pulmonary vein isolation procedure,  Medtronic will 
provide the target dates and windows  to complete each v isit either to the center , in-
home, virtual ly or by phone . Should  a subject visit fall outside the pre -specified 
window, a study deviation must  be reported,  and the original follow -up schedule 
maintained for subsequent  visits.  
Data analyses include data co llected at late and early follow -up visits.  Therefore, a late 
or early visit is preferred over a missed visit but  must be accompanied by  a deviation. 
Subjects will be followed until all subjects who underwent a  pulmonary vein isolation 
procedure reach the 6-month  visit. 
 
Table 6: Follow up visit  windows  
 
 
Study  Follow -up 
Visit  Window  
(Calculated days post -procedure  attempt)  
Window  Start 
(# of days)  Target 
(# of days)  Window  End 
(# of days)  
 
1 month  30 30 46 
6 month  180 180 194 
12 month  335 365 395 
18 month  515 545 575 
24 month  700 730 760 
30 month  880 910 940 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 31 of 92   36 month  1065  1095  1125  
42 month  1245  1275  1305  
Additional windows will be sent to centers if they extend beyond 42 months.  
 
6.18 Scheduled in-office follow -up visits 
 
6.18.1  One, Six and Every Six Month Visit Until Study Closure  
It is recommended that anti -hypertensive medications and dose not  be changed 
through the 6 month visit unless medically necessary. It  is recommended that 
subjects be off all antiarrhythmic medications within 90  days post cryoablation  
procedure.  
 
The following will be  collected:  
• blood and urine samples (not required after the 6 month  visit) 
• physical  exam  
• vital signs (including 3 blood pressure measurements according  to 
Appendix G: Blood Pressure Measurement  Procedures ) 
• review of  medications  
• assess for adverse  events  
• assess arrhythmias and symptoms, episodes of medical  care suggestive 
of arrhythmia including hospitalizations, office or ER  visits, or any AF -
related procedures such as cardioversions or  additional  ablations  
• interrogate the Reveal LINQ device, review prior CareLink reports  and the 
current interrogation for possible AF related  events  
 
Alternative methods of data collection may be necessary in the case of extenuating 
circumstances, such as a global pandemic, when subjects are prohibited from coming 
into the office for required assessments. For all assessments completed via alternative 
methods in these circumstances , sites are not required to enter a protocol deviation for 
missing , alternative , and/or late data collection. Data unable to be collected remotely or 
via an alternative method should be collected at the next possible in -person visit.  
In the event a subject is unable to return for an in -office follow -up visit, the alternative 
methods of obtai ning follow -up assessments are listed below:  
• In-home visit by trained and delegated site personnel or designee, i.e. home 
health care personnel. The following assessments may not be completed with an 
in-home visit:  
o CareLink  in-office interrogation. Guide a  subject through a full 
interrogation ( “Interrogate All ”) at the end of the follow -up visit  
o Renal Artery Imaging:  
▪ Make every effort to schedule in -person renal artery imaging as 
soon as possible.  
When possible, subjects may be referred to a local imaging c enter for assessment. Local 
imaging technicians would require study training and delegation prior to assessment.  In 
the event an in -home visit is not possible, the  alternate  methods for obtaining follow -up 
assessments are listed below : 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 32 of 92   • Virtual Visit, i.e. inclusive of video with study subject.  
▪ The following assessments may not be completed with a virtual visit:  
• Physical examination , limited review to be completed per physician 
discretion.  
• CareLink in-office interrogation . Guide a subjec t through a full 
interrogation ( “Interrogate All ”) at the end of the follow -up visit.  
• Laboratory Tests:  
o When possible, the subject should be referred to a local 
laboratory to collect samples. Laboratory Kits to be provided 
to subjects in advance of the vis it by study site . 
• Renal Artery Imaging:  
o Make every effort to schedule in -person renal artery imaging 
as soon as possible.  
o When possible, the subjects could be referred to a local 
imaging center for assessment. Local imaging technicians 
would require study training and delegation prior to 
assessment.  
 
▪ Office blood pressure unit to be provided to the subjects in advance of the 
visit by study site . Measurements collected by the patient may be collected 
and designated in the case report form . 
 
• Phone visit, i.e. no video with the subject .   
▪ The following assessments may not be completed with a phone visit:  
• Physical examination  limited review to be completed per physician 
discretion.  
• CareLink in-office interrogation . Guide a subject through a full 
interrogation ( “Interrogate All ”) at the end of the follow -up visit  
• Laboratory Tests:  
o When possible, the subject should be referred to a local 
laboratory to collect samples. Kits to be provided to subjects 
in advance of the visit  by study site . 
• Renal Artery Ima ging 
o Make every effort to schedule in -person renal artery imaging 
as soon as possible.  
o When possible, the subjects could be referred to a local 
imaging center for assessment. Local imaging technicians 
would require study training and delegation prior to 
assessment.  
 
▪ Office blood pressure unit to be provided to the subjects in advance of the 
visit. Measurements may be collected and designated as patient reported 
in the case report form.  
 
6.18.1.1  Six month  renal  artery  duplex  ultrasound  (Treatment  group  only)  
Renal artery duplex ultrasound (DUS) imaging will be performed only  for subjects 
who underwent the renal artery denervation. DUS will be  conducted  as per the 
DUS protocol provided by the DUS Core Lab. The DUS will  be assessed and if 
clinically significant stenosis (e.g. renal artery to aorta  peak systolic velocity ratio 
>3.5, or peak systolic velocity >200 cm/s with evidence  of post -stenotic turbulence) 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 33 of 92   is indicted, angiography will be performed. A  Core Lab will be responsible for 
comparing 6 mo nths angiogram with  baseline  angiography to evaluate any 
potential renal artery  stenosis.  
 
6.18.2  Atrial Arrhythmia  Management  
Subjects are required to have their Reveal LINQ interrogated monthly  via CareLink 
transmissions. For the monthly CareLink transmissions that  coincide  with a 
scheduled follow -up visit (i.e. 1 or 6 -month visits), a  CareLink transmission is not 
required but a device interrogation and data transfer  either  by save -to-disk or USB 
data transfer should be performed at the fo llow-up visit.  A CareLink transmission 
may be used a s a substitute for an in -office device interrogation. If CareLink 
transmissions become unavailable, centers may be required  to submit CareLink 
reports to Medtronic by uploading them to a secure server  or by sending printed 
versions of the reports. Complete a final  manual  transmission upon study  exit. 
 
6.19 Unscheduled follow -up visits 
An unscheduled visit is defined as any study -related visit which does not  occur  within 
the designated visit window of a scheduled follow up visit. Subjects who  are seen 
outside of their regularly scheduled follow up visit for arrhythmia symptoms  or 
suspected symptoms associated with renal denervation should have  unscheduled  
procedures and data collection  completed.  
The foll owing will be  collected:  
• blood and urine samples  (optional)  
• physical  exam  
• vital signs (including 3 blood pressure measurements according  to 
Appendix G: Blood Pressure Measurement  Procedures ) 
• review of  medications  
• assess for adverse  events  
• assess arrhythmias and symptoms, episodes of medical care suggestive  of 
arrhythmia including hospitalizations, office or ER visits, or any  AF-related  
procedures such as cardioversions or additional  ablations  
• interrogate the Reveal LINQ device, review prior CareLink reports and  the 
current interrogation for possible AF related  events  
 
6.20 System modification for Reveal  LINQ  
A system modification will be reported in the event the Reveal LINQ  requires invasive 
modification (e.g. rep osition, explant, replacement). In the event of  a system 
modification, the follow -up visit schedule for the subject will  remain unchanged. If the 
device is explanted and a replacement will not be inserted,  the subject should continue 
to stay in the  study.  
 
6.21 Permissible repeat  ablation  
All subjects may have one repeat ablation procedure within Days 0 -90 after  the first 
ablation if the following criteria are  met: 
• Inclusion  criteria:  
▪ Recurrent or a new onset atrial  tachycardia  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 34 of 92   • Exclusion  Criteria:  
▪ Active systemi c infection  
▪ Condition where manipulation of the catheter within the heart  would be 
unsafe (e.g. intracardiac mural  thrombus)  
▪ Cryoglobulinemia  
▪ Myocardial infarction, unstable angina pectoris, syncope,  PCI/PTCA, or 
coronary artery stenting within 3 months of the repeat  ablation  
▪ Cerebrovascular accident or TIA within 1 month of the  repeat 
ablation  
▪ Presence or a permanent pacemaker, biventricular pacemaker,  atrial 
defibrillator or any type of implantable cardiac defibrillator (with  or without 
biventricular pacing  function)  
 
• Re-ablation assessment is performed as  follows:  
o Physical examination, NYHA cardiac functional class, office  blood  
pressure and review of medications and  symptoms.  
o Study status post re -ablation: The subject’s procedures and  follow  up 
visit/assessments will continue based on the initial  cryoablation  
procedure date. A re -ablation of a study subject under this  section  is not 
an AF  Intervention.  
Other ablation techniques may be used as outlined in Section 6.10.  
 
6.22 Repeat renal artery  denervations  
Repeat renal artery denervations are not allowed at any point during the  study.  
 
6.23 Recurrence of atrial fibrillation  
Documentation of AF recurrence must be p rovided to the sponsor and  additional  source 
documents may be requested. Documentation of AF must include  the following:  
• Reveal LINQ rhythm recording (EGM)  
 
6.24 Study  exit 
Contact the subject to review medications, adverse events, episodes of  medical  care 
suggestive of arrhythmia including hospitalizations, office or ER visits,  and any AF -
related procedures such as cardioversions or additional ablations.  Have the subject 
manually transmit data from their Reveal LINQ device at study  exit. 
Subjects may be exi ted from the study for any of the following  situations:  
• Subject has completed  follow -up 
• Subject with LINQ battery at end of life, having completed at least 6 months of 
study follow -up 
• Subject lost to  follow -up 
• Subject  death  
• Subject did not meet inclusion/exclusion  criteria  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 35 of 92   • Subject not  randomized  
• Subject did not provide consent or data protection  authorization  
• Subject chooses to withdraw (e.g., consent withdrawal, relocation  to 
another geographic  location)  
• Investigator deems withdrawal necessary ( e.g. medically  justified,  
inclusion/exclusion criteria not met, failure of subject to maintain  adequate 
study  compliance)  
Once a subject is randomized, all efforts should be made to continue following  the 
subject until study  closure.  
 
6.24.1  Lost To Follow -Up 
In the case that the subject is determined to be lost to follow -up, details of  a 
minimum of two attempts and the method of attempt (e.g., one letter and  
one phone record or two letters) to contact the subject must be recorded.  In 
addition, follow the regulations set forth by the governing  IRB/MEC . 
 
6.24.2  Subject -Initiated  Withdrawal  
If subject chooses to withdraw, document date and reason for  exit. 
 
6.24.3  Early Exit for Any Reason  
Prior to an early exit of a subject from the study, all efforts should be made  
to continue following the subject until all serious unresolved procedure or  
device related adverse events, as classified by the investigator, are 
resolved or  they are unresolved with no further actions planned. Report any 
changes to  the outcome before exiting  the subject.  
 
7. INVESTIGATIONAL DEVICE STORAGE, HANDLING  
AND  TRACEABILITY  
7.1 Symplicity Spyral Renal Denervation  System  
In Europe, the study will utilize the commercially available  Symplicity Spyral 
Renal Denervation System (Symplicity  Spyral Catheter and Symplicity G3 
Generator) with no study driven changes to the product or labeling  and are 
considered non -investigational . Product ordering is the responsibility of the 
center personnel. The products may be stored the same as other commercially 
released prod uct.  
In the US, c omponents of the Symplicity Spyral Renal Denervation System are 
considered  investigational.  Investigational product will be distributed to a center 
only when Medtronic  has received all required documentation and has notified 
the center of  center  readiness. Distribution of the investigational product to 
study centers during  the clinical study will be managed by Medtronic. 
Investigational product must  be stored in a secure location at the center. It is 
the responsibility of the  investigator to correctly handle, store, and track the 
investigational products.  Investigational  products will be used only in the study 
according to the CIP.  
For the US, sites, all Symplicity  Spyral  Renal  Denervation System components 
used/attempted will be tracked and must  be treated as investigational for this  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 36 of 92   study.  Investigational product disposition logs will be provided to the center 
and used  for tracking of all investigational products during the study. The  
investigational  product distribution logs are  to be used for the Symplicity 
Spyral  Catheter, Symplicity G3 Generator, power cord and foot switch . The 
logs must  be maintained at each US center and updated when investigational 
product is  received,  opened, used/attempted, disposed of or returned to 
Medt ronic, see Table 7. 
 
7.2 Arctic Front Advance and Freezor MAX  Cardiac Cryoablation  
Catheter s 
In Europe, the study will utilize the market -released Arctic Front Advance /Arctic 
Front Advance Pro  and Freezor MAX  Cardiac  Cryoablation Catheter s with no 
study driven changes to the product or labeling  and are considered non -
investigational . Product ordering is the responsibility of the center personnel. 
The products may be stored the same as other commercially released produ ct.  
In the US, t he Arctic Front Advance /Arctic Front Advance Pro  and Freezor MAX  
Cardiac Cryoablation Catheters will be  considered  investigational when used in 
the persistent AF population  with an AF episode duration of 6 months  or longer , 
however, tracki ng of  the catheter will start when the packaging is opened with 
the intention of using for  the clinical study, regardless of the subjects AF 
diagnosis. Product ordering will be  the responsibility of center personnel. The 
products may be stored the same as other commercially released product.  It is 
the responsibility of the investigator  to correctly track the  products.  
In the US, p roduct disposition logs will be provided to the center and used for 
tracking of  the Arctic Front Advance /Arctic Front Advance  Pro and Freezor 
MAX  Cardiac C ryoablation  Catheters. The logs must be maintained at  each 
center and updated when product is opened, used/attempted, disposed of  or 
returned to Medtronic, see Table 7. 
 
7.3 Final product  disposition  
In the US, a ll unused Symplici ty Spyral Renal Denervation System components 
must be returned  to Medtronic upon study closure at the center or earlier. The 
product disposition  log must be updated with the final device disposition. If any 
Medtronic products  are suspected in a device deficiency or Unanticipated 
Adverse Device Effect  (UADE), make every effort to return them to Medtronic. 
Contact your local Medtronic  field personnel or clinical study manager to receive 
a return mailer kit if used  product needs to be sent back to  Medtronic . 
 
Table 7: US Product tracking  requirements  
 
 Symplicity  Renal Denervation  
System (Symplicity  Spyral  
Catheter, Symplicity  G3 Generator,  
power cord  and foot  switch ) Cardiac Cryoablation  
Arctic Front 
Advance/Arctic Front 
Advance Pro and 
Freezor MAX 
Catheters  
Receipt  x  
Opened  x x 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 37 of 92   Used/Attempted  x x 
Unopened  x  
Returned or  disposed  x x 
 
8. STUDY  DEVIATIONS  
A study deviation is defined as an event within a study that did not occur according  to 
the CIP or  CTA.  
Prior approval by Medtronic is expected in situations where the investigator  
anticipates, contemplates, or makes a conscious decision to deviate. Prior approval is 
not required  when a deviation is necessary to protect the safety, rights or well -being of 
a subject in  an emergency or in unforeseen situations beyond the investigator’s 
control (e.g.  subject failure to attend scheduled follow -up visits, inadvertent loss of 
data due to  computer  malfunction, inability to perform r equired procedures due to 
subject  illness).  A study deviation is not required if a subject misses a monthly LINQ 
manual interrogation.  
All study deviations must be reported on the CRF regardless of whether  medically 
justifiable, pre -approved by Medtronic, an inadvertent occurrence, or taken to protect  
the subject in an  emergency.  
In the event the deviation involves a failure to obtain a subject’s consent or  is made  to 
protect the life or physical well -being of a subject in an emergency, the deviation must  
be reported to the IRB /MEC  as well as Medtronic within five working days. Reporting 
of all  other  study deviations should comply with IRB /MEC  policies and must be 
reported to Medtronic  as soon as possible upon the center becoming aware of the 
deviation. Refe r to Investigator Reports, Table 11  for specific deviation reporting 
requirements and timeframes  for reporting to Medtronic and the  applicable regulatory 
body(s). 
Medtronic is responsible for analyzing deviations, assessing their significance,  and 
identifying any additional corrective and/or preventive actions (e.g. amend the  CIP, 
conduct additional training, or terminate the investigation). Repetitive or  serious  
investigator compliance issues may result in initiati on of a corrective action plan with  
the investigator and center, and in some cases, necessitate suspending enrollment 
until the problem is resolved or ultimately terminating the investigator's participation in 
the study. Medtronic will provide center -speci fic reports to investigators summarizing  
information  on deviations that occurred at the investigational center on a periodic  
basis.  
 
9. ADVERSE  EVENTS  AND DEVICE DEFICIENCIES  
Timely, accurate, and complete reporting and analysis of safety information for  
clinical studies are crucial for the protection of subjects. Reporting and analysis of 
safety  data are mandated by regulatory authorities. Medtronic has established 
procedures  in conformity with regulatory requirements to ensure appropriate 
reporting of  safety information. This study is conducted in accordance with these 
procedures  and regulations.  
Since the safety reporting requirements and classification systems vary for each 
regulatory agency, requirements from all geographies are taken into account fo r the 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 38 of 92   collection and reporting of safety information.  
 
9.1 Adverse event and device deficiency definitions  
Where the definition indicates “device”, it refers to any device used in the  study. 
This might be the devices under investigation or any market released  
component  of the two  systems.  
For the purpose of this study, all Adverse Events (AEs) and Device 
Deficiencies (DDs) will be classified according to ISO 14155:2011 . 
 
Table 8: Adverse event  definitions  
 
General  
Adverse Event  (AE) Any untoward medical occurrence, unintended disease or injury, or  untoward 
clinical signs (including abnormal laboratory findings) in subjects whether or  not 
related to the investigational medical  device.  (ISO 14155:2011 3.2)  
 
NOTE 1 : This definition includes events related to the investigational medical 
device or the comparator.  
NOTE 2: This definition includes events related to the procedures involved.  
NOTE 3: For users or other persons, th is definition is restricted to events related 
to investigational medical devices.  
Adverse Device Effect 
(ADE)  
 Adverse event related to the use of a medical device  (ISO 14155:2011 3.1)  
 
Note 1 : This definition includes adverse events resulting from  
insufficient or inadequate instructi ons for use, deployment,  
implantation, installation, or operation, or any malfunction of the  
medical device.  
Note 2 : This definition includes any event resulting from an error  
use or from intentional misuse of the medical device . 
 
Hospitalization  A hospital admission lasting more than 24 hours or which includes an  overnight 
admission.  
 
 
  
Relatedness  
Procedure  related  An adverse event that occurs due to any portion of the cryoablation or  renal 
denervation procedures related to the study.  
 
Cryoablation procedure related : event is related to any portion of  the 
procedure that encompasses  cryoablation.  
 
Renal angiogram : event is related to any portion of the procedure  that 
encompasses the renal  angiogram.  
 
Renal denervation procedure related : event is related to any portion of  the 
procedure that encompasses renal  denervation.  
 
Reveal LINQ insertion procedure related : event is related to any portion of  the 
procedure that encompasses insertion of the Reveal LINQ  device. 
 
Procedure related : if it cannot be determined which portion of the procedure  an 
event is related  to. 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 39 of 92   System  related  Cryoablation system related : event that results from the presence  or 
performance (intended or otherwise) of the cryoablation  system.  
 
Symplicity Renal Denervation system related : event that results from  the 
presence or performance (intended or otherwise) of the Symplicity  Renal 
Denervation system (Symplicity Spyral Catheter and Symplicity G3  Generator).  
 
Reveal LINQ  system related : event that results from the presence  or 
performance (intended or otherwise) of the Reveal LINQ  device.  
 
Other system related : An adverse event that results from the presence  or 
performance (intended or otherwise) of any device/tool used not related to  the 
cryoablation, renal angiogram, renal denervation procedure or Reveal  LINQ 
system.  
Cardiovascular  related  An adverse event relating to the heart and the blood vessels or  circulation.  
Seriousness  
Unanticipated  Adverse 
Device Effect  (UADE)  Any serious adverse effect on health or safety or any life -threatening problem  or 
death caused by, or associated with, an (investigational) device, if that  effect, 
problem, or death was not previously identified i n nature, severity, or degree  of 
incidence in the CIP or applicable (including a supplementary plan  or 
application), or any other unanticipated serious problem associated with a  device 
that relates to the rights, safety, or welfare of subjects. (21 CFR  812.3(s))  
Serious Adverse  Event 
(SAE)  Adverse event  that 
a) led to  death,  
b) led to serious deterioration in the health of the subject, that either resulted  in 
• a life -threatening illness or injury,  or 
• a permanent impairment of a body structure or a body function,  or 
• in-patient or prolonged hospitalization,  or 
• medical  or surgical  intervention  to prevent  life-threatening  illness  or 
injury  or permanent impairment to a body structure or a body  
function,  
b) led to fetal distress, fetal death or a congenital abnormality or birth  defect   
(ISO 14155:2011 3.37)  
 
NOTE : Planned hospitalization for a pre -existing condition, or a  procedure 
required by the CIP, without serious deterioration in health, is not considered  a 
serious adverse  event.  
Serious Adverse 
Device Effect (SADE)  Adverse device effect that has resulted in any of the consequences characteristic 
of a serious adverse event.  
(ISO 14155:2011 3.36)  
 
  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 40 of 92   Complication  An adverse event that results in death, involves any termination of a  significant 
device function, or requires  intervention.  
 
Noninvasive : noninvasive, when applied to a diagnostic device or  procedure, 
means one that does not by de sign or intention:  
(1) Penetrate or pierce the skin  or mucous membranes of the body, the ocular 
cavity, or the  urethra  
• Penetrate: to pass, extend, pierce, or diffuse into or through  something; 
to enter by overcoming resistance; to gain entrance  to 
• Pierce: to force a way into or through something  or 
(2) enter the ear beyond the external auditory canal, the nose beyond the  nares, 
the mouth beyond the pharynx, the anal canal beyond the rectum, or  vagina 
beyond the cervical os. For purpose of this part, blood sampling that  involves 
simple venipuncture is considered no ninvasive, and the use of surplus  samples 
of body fluids or tissues that are left over from samples taken  for non -
investiga tional  purposes  is also considered  noninvasive.  (21 CFR 812.3(k))  
Observation  Any adverse event that is not a  complication.  
Timing  
Pre-procedure  An adverse event that occurs after the consent form has been signed but  before 
access to the vasculature has occurred for the study required  procedures.  
Cryoablation -procedure  An adverse event that occurs during the cryoablation procedure from the time  of 
the first sheath access to the vasculature until the last sheath for cardiac  ablation 
is removed.  
Renal  angiogram - 
procedure  An adverse event that occurs during the renal angiogram procedure from  the 
time of the first sheath access to the vasculature for the angiogram until the  last 
sheath for angiogram is  removed.  
Renal  denervation - 
procedure  An adverse event that occurs during the renal denervation procedure from  the 
time of the first sheath access to the vascu lature until the last sheath for  renal 
denervation has been  removed.  
Post-cryoablation/Post - 
renal  denervation  An adverse event that occurs after the removal of all cardiac ablation,  renal 
denervation and EP catheters used in the  procedures.  
 
 Other  
Device  deficiency  Inadequacy of a medical device with respect to its identity, quality,  durability, 
reliability, safety or performance.  (ISO 14155:2011 3.15)  
 
NOTE: Device deficiencies include malfunctions, use errors and inadequate 
labeling . 
Unavoidable  Adverse 
Event  An Adverse Event inherent to a surgical procedure that is expected to occur in  all 
subjects for a projected duration according to the Investigator’s  opinion, 
including, but not limited to those provided below. These are not report able AEs 
unless they occur after or last longer than the timeframe. If any other  events 
below are classified as serious they must be reported as an adverse  event.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 41 of 92     
Event  Description  Timeframe 
(hours)  from 
the Surgical 
Procedure   
Anesthesia related nausea /  vomiting  24 
Low-grade fever (<100°F or  37.8°C)  48 
Incisional  pain 72 
Mild to moderate bruising /  ecchymosis  168 
Sleep problems  (insomnia)  72 
Back pain related to laying on  table  72 
Shoulder/arm/leg  pain/discomfort/stiffness 
related to immobilization during  procedure  72 
 
 
9.2 Adverse event and device deficiency assessment  
 
9.2.1  Adverse Events  
To ensure that all AEs which are potentially relevant are collected, all  system  
related, procedure related, cardiovascular related and serious AEs will  be collected 
throughout the study duration, starting at the time of signing  the consent form. 
Reporting of these events to Medtronic will occur on an AE  form, including a 
description of the AE, date of AE onset, treatment, resolution,  and assessment of 
both the seriousness and the relatedness to the  device.  
Exceptions  include:  
• Documented pre -existing conditions are not considered AEs unless  the 
nature or severity of the condition has  worsened  
• Recurrence of AF event unless an invasive action was  taken  
• Unavoidable AEs unless the AE worsens or is present outside  the 
stated timeframe listed in Table 8 
For AEs that require immediate reporting (see Table 9: Adverse  Event  Reporting ), 
initial reporting may be done by phone, fax, email or on the  CRF completing as 
much information as possible. The completed AE CRF must  be submitted to 
Medtronic as soon as possible. Each AE must be  recorded on  a separate AE Form. 
Subject deaths are also required to be reported. Refer  to Section 9.5 for Subject 
Death collection and reporting  requirements.  
 
9.2.2  Device Deficiency  
Device deficiency information will be collecte d throughout the study and reported to  
Medtronic. Note that device deficiencies that result in an adverse device effect (ADE) 
to the subject should be captured as an Adverse Event only.  
 
Device deficiencies that did not lead to an AE but could have led to a Serious  Adverse  
Device Effect (SADE) (i.e., if suitable action had not been taken, if intervention had 
not been made, or if the circumstances had been less fortunate) require immediate 
reporting  (see Table 9). 
 
Initial reporting may be done on the CRF co mpleting as much information as is 
available . The original completed Device Deficiency CRF must be sent to Medtronic 
as soon as possible.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 42 of 92    
9.2.3  Processing Updates and  Resolution  
For any changes in status of a previously reported adverse event (i.e. change  in 
actions taken, change in outcome, change in relatedness), an update to  the original 
AE must be completed. All reported adverse events must be  followed  until the 
adverse event has been resolved, is unresolved with no further  actions  planned, the 
subject exi ts the study or until study closure, whichever  occurs first.  
In the event that a subject is exited from the study prior to study closure,  all efforts 
should be made to continue following the subject until all  reported  adverse events 
are resolved or they ar e unresolved with no further  actions planned.  
At the time of study exit, all adverse events with an outcome of  “Unresolved,  further 
actions or treatment planned” must be reviewed and an update to  the original AE 
must be reported. At a minimum, if there are no changes to  the description, 
relatedness, test and procedures or actions taken, the  outcome must be updated to 
reflect “Unresolved at study  exit.”  
 
9.3 Market -released reporting  requirements  
Product complaint reporting is applicable to devices that  are market -released.  This 
includes when an AE is related to a market -released device during the  study. The 
reporting of product complaints is not part of the clinical study and should  be done in 
addition to the Adverse Event reporting requirements. Refer to local regulations for 
reporting  requirements.  
Product Complaint: Any written, electronic or oral communication that  alleges  
deficiencies related to the identity, quality, durability, reliability,  safety,  effectiveness or 
performance of a medical device that has been placed on  the market.  
It is the responsibility of the investigator to report all product  complaint(s) associated 
with a medical device distributed by Medtronic, regardless  whether  they are related 
to intended use, misuse or abuse of the produ ct. Reporting  must be done 
immediately and via the regular channels for market -released  products.  
Medtronic will notify the regulatory authorities as applicable for the  following  incidents 
immediately upon learning of  them:  
• Any malfunction or deterioration in the characteristics  and/or  performance 
of a device, as well as any inadequacy in the labeling  or instructions for 
use which led or might have led to the death or  serious  deterioration in the 
state of health of a patient, user, or other  person. 
• Any technical or medical reason resulting in withdrawal of a device  from the 
market by the  manufacturer.  
• A serious deterioration in the state of heath  includes:  
▪ Life-threatening illness or  injury  
▪ Permanent impairment of a body function or permanent  damage to 
a body  structure  
▪ A condition necessitating medical or surgical intervention  to 
prevent permanent impairment to a body structure or a  body 
function  
9.4 Adverse event and reporting  requirements  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 43 of 92   Regulatory reporting of AEs will be completed according to  regulatory requirements. 
Refer to Table 9: Adverse Event Reporting  for a list of  required  investigator reporting 
requirements and timeframes, and of required  Medtronic reporting requirements and  
timefra mes.  
It is the responsibility of the investigator to abide by any additional AE  reporting 
requirements stipulated by the  IRB/MEC . 
For AEs that require immediate reporting, initial reporting may be done  by contacting 
the study sponsor per the sponsor contact information provided in  this document.  
Table 9: Adverse Event  and Device Deficiency  Reporting  Requirements  
 
Unanticipated Adverse Device Effects  (UADEs)  
Investigator submit  to: 
Medtronic  US: Submit  as soon  as possible,  but no later than within  10 working  days  after the investigator  
first learns of the event. (21 CFR  812.150(a)(1))  
Europe:  Immediately after the Investigator first learns of the event or of new information in 
relation with an already reported event.  
IRB/MEC  US: Submit  as soon as possible,  but no later than within  10 working  days  after the investigator  
first learns of the event. (21 CFR  812.150(a)(1))  
Europe:  Submit to MEC per local reporting requirement.  
Regulatory 
Authorities  Europe: Submit to regulatory authority per local reporting requirement.  
Sponsor submit  to: 
Investigator  All geographies: Submit as soon as possible, but no later than within 10 working days 
after the sponsor  first learns of the event. (21 CFR  812.150(b)(1))  
Regulatory 
authorities  US: Submit as soon as possible, but no later than within 10 working days after the 
sponsor  first learns of the event. (21 CFR  812.150(b)(1))  
Europe: Submit to regulatory authorities per local reporting requirement.  
 
IRB/MEC  US: Submit as soon as possible, but no later than within 10 working days after the 
sponsor  first learns of the event. (21 CFR  812.150(b)(1))  
Europe:  Submit to IRB/MEC per local reporting requirement  
All other Adverse  Events  
Investigator submit  to: 
Medtronic  All geographies: Submit or report as required for local reporting requirements and  protocol.  
IRB/MEC  All geographies: Submit to IRB /MEC  per local reporting  requirements.  
Regulatory 
authorities  All geographies: Submit to regulatory authority per local reporting requirement.  
Sponsor submit to:  
Regulatory 
Authorities  All geographies: Submit to regulatory authority per local reporting requirement.  
Device Deficiencies with SADE Potential  
Investigator submit  to: 
Medtronic  All geographies: Submit or report as required for local reporting requirements and  protocol.  
IRB/MEC  All geographies: Submit to IRB/MEC per local reporting  requirements.  
Regulatory 
authorities  All geographies: Submit to regulatory authority per local reporti ng requirement.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 44 of 92   Sponsor submit to:  
Regulatory 
Authorities  All geographies: Submit to regulatory authority per local reporting requirement.  
All other Device Deficiencies  
Investigator submit  to: 
Medtronic  All geographies: Submit in a timely manner after the investigator first learns of the event.  
IRB/MEC  All geographies: Submit to IRB/MEC per local reporting  requirements.  
Regulatory 
authorities  All geographies: Submit to regulatory authority per local reporting requirement.  
 
9.5 Subject  death 
 
9.5.1  Death Data Collection  
All subject deaths must be reported by the investigator to Medtronic on  an 
adverse event CRF (SAE leading to death) as soon as possible after  the 
investigator first learns of the death. There should be one SAE with  the outcome 
of death.  
A copy of the death certificate, if available and allowed by state/local  law, should be 
sent to the Medtronic clinical study team. When a death occurs in  a hospital, a copy 
of the death summary report and all relevant hospital  records  should be sent to the 
Medtronic clinical study team, if available. If an autopsy  is conducted, the autopsy 
report should also be sent to the Medtronic  clinical  study team if available and 
allowed by state/local law.  When the death  occurs at a remote center, it is the 
investigative center’s responsibility to  attempt retrieval of information about the 
death. In summary, the following data will  be collected:  
• Date of  death  
• Detailed description of  death  
• Cause of  death  
• Relatedness to system and/or  procedure  
• Death s ummary/hospital records (if available and allowed by  state/local  
law) 
• Autopsy report (if available and allowed by state/local  law) 
• Death certificate (if available and/or allowed by state/local  law) 
 
9.5.2  Death Classification and  Reporting  
Sufficient information will be required in order to properly classify the  subject’s 
death. The Investigator shall classify each subject death per the  following  
definitions:  
Cardiac Death : A death directly related to the electrical or  mechanical  dysfunction 
of the  heart. 
Sudden Cardiac Death (SCD) : Natural death due to cardiac causes,  indicated  by 
abrupt loss of consciousness within one hour of the onset of  acute symptoms; 
preexisting heart disease may have been known to be present,  but the time and mode 
of death are unexpected. If time of onset cannot  be determined, SCD will alternatively 
be defined as any unexpected cardiac  death occurring out of the hospital or in the 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 45 of 92   emergency room as dead on  arrival.  
Non-sudden Cardiac Death : All cardiac deaths that are not cl assified as  sudden  
deaths, including all cardiac deaths of hospitalized subjects on  inotropic support.  
Non-cardiac Death : A death not classified as a cardiac  death.  
Unknown Cardiac Classification : Unknown death classification is intended  for use 
only when there is insufficient or inadequate information to classify  the death.  
The CEC will review deaths and provide a final adjudication of the  cardiac  
classification.  
 
9.6 CEC  review  
At regular intervals, an independent CEC will conduct a medical review of, at  a minimum, 
all deaths and endpoint related  events.  
The CEC will consist of a minimum of three (3) non -Medtronic  employed  physicians 
that are not participating investigators for the study, including a  CEC chairperson. At 
least two CEC members must adjudicate, at a minimum,  all deaths and serious AEs 
related to any component of the systems  under  investigation. All other events may 
be adjudicated by at least one member of  the CEC.  
The CEC members may be blinded to the subjects’ randomization  assignmen t and/or 
other data or procedures that may influence their  decision.  
Medtronic personnel may facilitate and participate in a CEC meeting but will  be 
non-voting  members.  
For adverse events, and deaths, reviewed by the CEC, Medtronic will provide  the CEC 
with the Investigator’s description and classification. The CEC is  responsible for 
reviewing the Investigator’s assessment and supportive documentation  (when  
available), reviewing applicable definitions, and determining final classifications  for all 
adjudi cation  parameters.  
If the CEC disagrees with the investigator’s classification of the event, the  rationale will 
be provided to the investigator. If the investigator agrees with the  CEC’s  adjudication, 
the CRF documenting the AE or AE update will be  updated  accordingly.  
If the investigator does not agree with the CEC’s adjudication classification,  both 
determinations will be provided within the final report; however,  the CEC’s  adjudication 
will be used for data analysis. The disagreement will also be  include d in reporting to 
IRB/MEC  and regulatory authorities, if  required.  
 
9.7 Adverse event classification  
All reported adverse events and device deficiencies will be reviewed by  a Medtronic 
representative. AEs will be classified according to the  definitions  provided.  
Upon receipt of adverse events at Medtronic, a Medtronic representative  will review the 
adverse event/device deficiency for completeness and accuracy  and when necessary 
will request clarification and/or additional information from  the Investigator. Medtronic 
will utilize MedDRA, the Medical Dictionary for  Regulatory  Activities, to assign a 
MedDRA term for each adverse event based on  the information provided by the  
investigator.  
Adverse Events and Deaths will be classified according to the standard  definitions  as 
outlined  below:  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 46 of 92    
Table 10: Adverse event and subject death classification  responsibilities  
 
What is  classified?  Who  classifies?  Classification Parameters   
Timing of the  Event  Investigator  Pre-procedure, cryo-procedure, renal  denervation - 
procedure, assessment,  post-procedure  
 
 
Relatedness   
Investigator  Symplicity System, Arctic Front Cardiac  Cryoablation System, 
renal artery denervation procedure,  cryoablation procedure, 
Reveal LINQ system and procedure  other procedures  
Sponsor  Same as  Investigator  
 
Severity  Investigator  SAE 
Sponsor  SAE, UADE, Complication or Observation (for all system  
or procedure related adverse  events)  
 
 
Diagnosis  Investigator  Based on presenting signs and symptoms and  other 
supporting  data 
Sponsor  MedDRA term assigned based on the data provided  by 
investigator  
Death 
Classification1 Investigator  Cardiac, Sudden Cardiac, Non -sudden Cardiac,  Non- 
Cardiac,  Unknown  
1Deaths will only be adjudicated to death classification. All other adjudications information will  be taken from 
the corresponding AE with an outcome of  death
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 47 of 92   10. RISK  ANALYSIS  
Medtronic follows rigorous Quality Assurance and Control procedures throughout the  
life of a product, fr om the business analysis phase through development, market  
release,  and post -market  surveillance.  
There are potential risks and side effects associated with these procedures.  The 
investigator shall describe risks in further detail when asked by the  subject.  The 
current Instructions for Use  document  should be referenced as the list below may only 
be updated  periodically  during the course of the study.    
Possible additional risks for participating in this study include the following  (although 
others ar e possible):  
• Mild skin discomfort or irritation -redness sensitivity of the skin cause during  
or after the procedures (e.g. electrodes used with the ECG and Holter  
recorder  might cause mild skin discomfort or irritation or some skin 
discomfort  following ele ctrode removal or tape  removal).  
• Death -a complication or deterioration of health ultimately leading to a  
patient’s death.  
• Cardiopulmonary arrest -cessation of blood circulation and/or respiration 
due to dysfunction of the heart and/or  lungs.  
• Coronary artery spasm -constriction of a blood vessel . 
• Heart rhythm disturbances /Arrhythmia -disruption of normal heart rate or 
rhythm,  including  bradycardia treated with  atropine.  
• Embolism -formation and dislodgement of a blood clot (thrombus)  or 
dislodgemen t of cholesterol/plaque within the blood vessel, which  travels  
downstream into small vessels, blocking blood flow and causing temporary  
or permanent damage to organs distal to blockage. Emboli are known to  
cause myocardial infarction, stroke or kidney damage, peripheral ischemia 
and may ultimately lead to incapacitation or  death.  
• Complications at catheter insertion site in the  groin:  
o Pain-discomfort at the catheter insertion site that can range from mild  
to severe.  
o Hematoma/Bruising /Ecchymosis -a collection of blood in the tissue 
surrounding  the catheter insertion  site. 
o Pseudoaneurysm -a collection of blood in the tissue surrounding  
the catheter insertion site due to ongoing leaking of blood from a  
blood  vessel.  
o AV fistula -an abnormal connection between an artery and a vein  
(i.e., cause by needle insertion through the femoral artery and  
vein).  
o Infection -localized redness, heat swelling and pain at the  
catheter insertion  site. 
o Significant bleeding -blood loss from the catheter insertion site  
requiring surgery or transfusion of 2 or more units of packed red 
blood  cells (PRBCs).  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 48 of 92   • Retroperitoneal bleeding -bleeding into the retroperitoneal  space.  
• Vascular complications requiring surgery -damage to an artery (e.g. femoral)  
or vein requ iring surgical  repair.  
• Perforation of a blood vessel -unintended puncture through the wall of a  
blood  vessel, such as a renal artery, requiring  repair.  
• Dissection of a blood vessel /pulmonary vein dissection -a tear within the wall 
of a blood vessel, which  allows blood to separate the wall  layers.  
• Hypotension -low blood  pressure.  
• Hypertension -high blood  pressure.  
• Nausea -a sensation of unease and discomfort in the upper stomach with an  
urge to  vomit.  
• Vomiting -forceful expulsion of stomach contents through the mouth and/or  nose.  
• Pericardial effusion -fluid collecting in the sac that surrounds the  heart . 
• Cardiac tamponade -pressure on the heart as a result of fluid collecting in the  
sac surrounding the  heart . 
• Esophageal injury -damage to your swallowing  tube 
o Atrio-esophageal fistula -abnormal passageway between the heart  
and esophagus . 
• Phrenic nerve injury -damage to the nerve that controls  breathing . 
• Pulmonary vein stenosis -blockage in the blood vessels takes blood from  the 
lungs to the  heart. 
 
• Endocarditis -inflammation of the inner surface of the  heart . 
• Infection (e.g. Pericarditis -inflammation of the sac that surrounds the  heart , 
sepsis -infection throughout the body, urinary -infection of the urinary system) . 
• Pneumothorax -collapsed  lung. 
• Hemothorax -collection of blood around the  lungs . 
• Pleural effusion -collection of extra fluid around the  lungs . 
• Pneumonia -lung infection . 
• Pulmonary edema -excess fluid in the lungs . 
• Pulmonary hemorrhage -bleeding from the lungs . 
• Injury to lung  (e.g. bronchial  lesion , bronchial constriction , bronchial fistula ) 
• Vagal nerve injury (e.g. Gastroparesis -delayed gastric emptying)  
• Visual changed (e.g. blurred vision)  
• Complications associated with contrast agents -adverse effects of contrast  
agents used during the proced ure (e.g. allergic reaction or radio contrast  
nephropathy).  
• Complications associated with medications commonly utilized during  the 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 49 of 92   procedure -known risks of medications commonly used during the procedure  
(e.g. narcotics, anxiolytics, other pain medications,  anti-vasospasm agents).  
 
There are additional risks that could possibly be associated with the  denervation  
procedure/therapy. These potential risks have not yet been quantified, but may  include:  
• Pain-discomfort that can range from mild to severe that may occur peri - 
and/or  post-procedure.  
• Damage to one or both kidneys and/or loss of kidney function -perforation  of 
kidney or an occlusion or blood flow to the kidney (e.g. from stenosis  or 
embolism) and/or reduction of glomerular filtration rate. If severe enough,  
this could require  dialysis.  
• Renal artery aneurysm -localized weakening and ballooning of the renal  
artery from the interventional procedure or the delivery of RF  energy.  
• Renal artery stenosis -narrowing of the renal artery due to the  
interven tional  procedure or the delivery of RF  energy.  
• Arterial spasm or constriction -acute or chronic narrowing of the renal  artery 
lumen diameter at denervation locations due to arterial muscle contraction,  
local tissue contraction or local  edema.  
• Thermal injury to the vasculature or other structure from energy  
application - damage to an artery, vein or other structure due to the 
delivery of RF  energy.  
• Hypertension -worsening high blood  pressure.  
• Hypotension -low blood pressure. Blood pressure reduction may oc cur too  
far and/or too quickly and may cause end organ  hypoperfusion.  
• Orthostatic hypotension -temporary reduction of blood pressure when going  
from lying to standing, coupled with symptoms (e.g. dizziness, light  
headedness).  
• Hematuria -blood in  urine.  
• Hemorrhage -significant blood  loss. 
• Proteinuria -elevated levels of protein in  urine.  
• Electrolyte disturbances -an imbalance of the electrolytes (sodium,  potassium).  
• Skin burn -damage to the skin caused by energy conduction via the ground  
pad used with the Symplicity Renal Denervation system (Symplicity Spyral  
Catheter  and Symplicity G3  Generator).  
 
There are additional risks that could possibly be associated with the Reveal  LINQ.  
 
• Rejection of the Reveal LINQ by your body, which may involve symptoms  
such as  swelling, redness, or other irritation at, or near, the implant  site. 
• Movement of the Reveal LINQ from its initial position or coming through the  
skin. 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 50 of 92   • Infection at the site of the  implant . 
• Over -sensing or under -sensing (incorrectly identifying too many or too few)  
times  where your heart may be showing a rhythm  problem . 
 
There are additional risks that could possibly be associated with the tests  and procedures 
performed for this study.  These potential risks are described  below.  
There are risks related to the blood tests required for the trial  [e.g., excessive  bleeding, 
fainting or light headedness, hematoma (bruising), infection, or the requirement  of multiple 
punctures to locate a vein to draw the  sample ]. 
The cryoablation and renal artery dene rvation involve exposure to a small amount  of radiation 
as part of the fluoroscopy procedure. Possible risks associated with this  are: 
• Increased risk of cancer and damage to the fetus of pregnant  women.  
• Increased radiation exposure time if an additional ab lation 
procedure  is necessary.  
• Radiation injury resulting in skin inflammation and  redness.  
There are risks of undergoing CT scan, Renal Angiography and chest x -rays.  These include: 
medication patches that can cause a skin burn and allergic reaction to  the contrast material (if 
used) and exposure to  radiation.  
There is a possibility of risks to an unborn child. These risks are unknown. Women  who are 
pregnant or expect to become pregnant during the course of the study are  excluded  from 
partici pating.  
This study may involve unknown or unforeseen side effects or complications other  than those 
mentioned above. If the above complications occur, they may lead to repeat  or prolonged 
hospitalization, repeat procedures, emergency surgery, other  emergen cy procedures or in rare 
cases,  death.  
 
10.1 Risk minimization  
The potential risks associated with these therapies were identified and have  been  
successfully mitigated. Any potential risks associated with this study are  further 
minimized by to following  ways:  
• Selecting qualified investigators and training study personnel on the  CIP. 
• Investigators and center staff will receive appropriate training prior to  any 
study  procedures.  
• The sponsor has also attempted to minimize risk to subjects  
implementing a Data Monitoring Committee to review safety issues as 
part of the  study.  Investigators will be actively involved in the procedures 
and follow -up of  the subjects undergoing these therapies. After 
treatment, subjects in  the Symplicity AF clinic al study will be followed at 
regular intervals to  monitor  the condition of their treatment and to assess 
any adverse  events.  
• Risks will be minimized by careful assessment of each subject prior  
to, during, and after procedures. Prior to treatment, it is  
recommended  subjects undergo a complete cardiac  evaluation.  
• Medtronic has further minimized the possibility of risks by:  implementing 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 51 of 92   quality control measures into production processes, providing guidelines  
for subject selection and evaluation, and providi ng adequate instructions  
and labeling.  
 
10.2 Potential  benefits  
Although no assurances or guarantees can be made, there is  reasonable 
expectation that adding the renal denervation procedure to pulmonary  vein 
isolation to treat paroxysmal and persistent AF may be beneficial to the  subject. 
Treatment with this system may reduce the sympathetic nerve activity to and  
from the kidneys, and cause a reduction in blood pressure. Evidence in the  
literature suggests that reduction of efferent sympatheti c nerve activity to the 
kidney can  a) cause relief of renal vasoconstriction, resulting in improved 
kidney function;  b) reduce sodium retention, which can improve the clinical 
condition of patients  with medical problems related to excess salt and water; 
and c) reduce the release  of renin -a renal produced hormone which is often 
elevated in patients with  either  severe hypertension or heart failure. 
Interference of afferent sympathetic  nerve activity from the kidneys can reduce 
central sympathetic act ivity, also  causing  reduction of blood  pressure .18,19,20    
The information gained from this study could result in the improved  management  of 
paroxysmal and persistent AF.  Additionally, information collected from  this study 
may assist in the design of new  product(s)/therapy(ies) and/or indications  for use. 
 
11. PLANNED STUDY CLOSURE, EARLY  TERMINATION  OF 
STUDY OR STUDY  SUSPENSION  
11.1 Planned study  closure  
Study Closure is a process initiated by distribution of an initial study closure  
letter. Study closure is defined as closure of a clinical study that occurs when  
Medtronic and/or regulatory requirements have been satisfied per the CIP 
and/or by  a decision by Medtronic or regulatory authority, whichever occurs 
first. The  study  closure process is complete upon d istribution of the Final 
Report or after  final payments, whichever occurs last. Ongoing IRB /MEC  
oversight is required until  the overall study closure process is  complete.  
 
11.2 Early termination or  suspension  
Early Termination of the Study is the closure of the  clinical study that occurs  
prior to meeting defined endpoints. This is possible for the whole study or a  
single center.  Study Suspension is a temporary postponement of study 
activities  related  to enrollment and distribution of the product. This is possib le 
for the whole  study  or a single  center.  
 
11.2.1  Study -Wide Termination or  Suspension  
Possible reasons for considering study suspension or termination of the  study  include 
but are not limited  to: 
• Adverse events associated with the system or product under  investigation  
which might endanger the safety or welfare of the  subject  
• Observed/suspected performance different from the product’s design  intent  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 52 of 92   • Decision by Medtronic or regulatory  body  
• Recommendation of early termination by the  DMC  
• Technical issues durin g the manufacturing process or with the  systems  
 
11.2.2  Investigator/ Center Termination or  Suspension  
Possible reasons for clinical investigator or center termination or  suspension  include 
but are not limited  to: 
• Failure to obtain initial IRB /MEC  approval or annual renewal of the  study  
• Persistent non -compliance to the clinical investigation (e.g. failure  to 
adhere to inclusion/exclusion criteria, failure to follow subjects  per 
scheduled  follow -ups) 
• Lack of  enrollment  
• Noncompliance to regulations and the terms of the Clinical Trial  Agreement  
(e.g. failure to submit data in a timely manner, failure to follow -up on  data 
queries and monitoring findings in a timely manner,  etc.) 
• IRB/MEC  suspension of the  center  
• Fraud or fraudulent misconduct is  discovered  
• Investigator request (e.g. no longer able to support the  study)  
 
11.3 Procedures for termination or  suspension  
 
11.3.1  Medtronic -Initiated  
• Medtronic will promptly inform the clinical investigators of the termination  or 
suspension and the reaso ns and inform the regulatory authority(ies)  where 
required  
• In the case of study termination or suspension for reasons other than  a 
temporary IRB /MEC  approval lapse, the investigator will promptly inform the  
IRB/MEC  
• In the case of study termination, the investigator must inform the  subjects and 
may inform the personal physician of the subjects to  ensure appropriate care 
and follow -up is  provided  
• In the case of a study suspension, subject enrollment must stop until  the 
suspension is lifted by  Medtronic  
• In the case of a study suspension, enrolled subjects should continue to  be 
followed out of consideration of their safety, rights and  welfar e 
11.3.2  Investigator -Initiated  
• The investigator will inform Medtronic and provide a detailed  written  
explanation of the termination or  suspension  
• The investigator will promptly inform the  institution  
• The investigator will promptly inform the  IRB/MEC  
• The investigator will promptly inform the subjects and/or the  personal  
physician of the subjects to ensure appropriate care and follow -up is 
provided  
• In the case of a study suspension, subjects enrolled should continue to  be 
followed out of consideration of th eir safety, rights and  welfare  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 53 of 92    
11.3.3  IRB/MEC -Initiated  
• The investigator will inform Medtronic and provide a detailed  written  
explanation of the termination or suspension within 5 business  days  
• Subject enrollment must stop until the suspension is  lifted  
• Subjects  already enrolled should continue to be followed in  accordance with 
IRB/MEC  policy or its determination that an overriding safety concern  or 
ethical issue is  involved  
• The investigator will inform his/her institution  
• The investigator will promptly inform the subjects, or  legally -authorized  
designees or guardians and/or the personal physician of the subjects,  with the 
rationale for the study termination or  suspension  
 
 
12. STATISTICAL METHODS AND DATA  ANALYSIS  
Statisticians employed by Medtronic or their  designees will perform the  statistical  
analyses described in this  section.  
 
12.1 Sample size  determination  
The overall study sample size is 70 randomized subjects that undergo  a 
pulmonary vein isolation procedure which is the required sample size for  the 
primary effectiveness  objective.  
 
Subjects that are enrolled in the study may not go on to be randomized due to  a 
variety of reasons, including elective withdrawal prior to randomization,  blood  
pressure measurements that do not meet study criteria, or rena l anatomy that  is 
found to be ineligible upon angiography. Based on the rate of  randomization  
among enrolled subjects in trials with similar screening criteria, up to 245  
subjects may need to be enrolled and undergo screening in order to ensure that 
70 subjects are  randomized.  Subjects who are randomized  and meet either  of 
the following two conditions do not count to ward  the 70 subjects randomized:  
• exit the study without undergoing a pulmonary vein isolation procedure  
• subjects  who are randomized to the treatment group and are found not 
to meet inclusion/exclusion criteria during the renal denervation 
procedure.  
 
All objectives will be analyzed once the last randomized  subject has completed 
the 6-month  follow -up visit . In addition, the primary effectiveness objective  will be 
analyzed  during interim analyses . These i nterim analyses  may be performed after 
32 and 50 subjects  have been  randomized and completed their 6 -month follow -up 
visit. If data are deemed to sufficient ly characterize th is study objective by the 
sponsor at one of these analyses, enrollment may be stopped . Analysis results 
will be included in the study report(s).  
 
12.2 General  considerations  
A modified intention -to-treat analysis will be performed and will serve as  the 
primary analysis for all objectives in this study. The modified  intention -to-treat 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 54 of 92   cohort will include all randomized subjects that undergo a pulmonary vein  
isolation  procedure (i.e. have a cryocatheter inserted). Patients that are 
randomized,  and meet either  of the following two conditions will not be included 
in this cohort:  
• exit the study without undergoing a pulmonary vein isolation procedure   
• subjects  who are ra ndomized to the treatment group and are found not 
to meet inclusion/exclusion c riteria during the renal denervation 
procedure . 
The Statistical Analysis Plan (SAP) will include a comprehensive description of  the 
statistical methods and reports to be included in the final study report. Any  change to 
the data analysis methods described in the CIP will require an amendment  only if it 
changes a principal feature of the protocol. Any other change to the  data analysis 
methods described in the protocol, and the justification for making  the change, will be 
described in the clinical study  repor t. 
 
12.3 Primary safety  objective  
The primary safety objective characterizes the rate of safety composite  events  (Table 
11) within each of the two study arms and also characterizes the  difference in the rates 
between study  arms.  
Safety Composite Events are events that are serious, occur within a specified time 
interval (see Table 11) starting when the subject undergoes the study pulmonary vein 
isolation procedure and meet the definition in Section 12.3.1 . The CEC adjudication will 
be used to classify subjects for this endpoint.  
 
Table 1 1: Safety composite events and onset  intervals  
 
 Serious Adverse Event   Onset Interval  
Death  1 month  
End-stage renal  disease  1 month  
Significant embolic  event  1 month  
Renal artery perforation requiring  intervention  1 month  
Renal artery dissection requiring  intervention  1 month  
Vascular  complications  1 month  
Hospitalization for hypertensive  crisis  1 month  
New renal artery  stenosis  6 months  
Cardiac  damage  1 month  
Pulmonary vein  stenosis  6 months  
Atrio-esophageal  fistula  6 months  
Arrhythmia  1 month  
Persistent phrenic nerve  palsy  6 months  
 
12.3.1  Event  Definitions  
 
12.3.1.1  End-stage renal disease defined as two or more eGFR  measurements  
<15mL/min/1.73m2 at least 21 days apart and requiring dialysis  for one or 
more of the following: volume management refractory  to diuretics, 
hyperkalemia unmanageable by diet and diuretics,  acidosis bicarbonate 
<18 unmanageable with HCO3 supplements,  or symptoms of uremia, 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 55 of 92   nausea,  vomiting.  
 
12.3.1.2  Significant embolic event resulting in end -organ damage  (e.g. 
kidney/bowel infarct, lower extremity ulceration or gangrene, stroke  or 
doubling of serum cre atinine confirmed by at least two  measurements at 
least 21 days apart).  Stroke is defined as a) rapid onset of a  focal  or 
global neurological deficit with at least one of the following:  change  in level 
of consciousness, hemiplegia, hemiparesis, numbness  or sensory loss 
affecting one side of the body, dysphasia or  aphasia,  hemianopia, 
amaurosis fugax, or other neurological signs  or symptoms consistent with 
stroke, b) duration of a focal or  global  
neurological deficit ≥24 h; OR <24h, i f therapeutic  intervention(s) were 
performed (e.g. thrombolytic therapy or intracranial  angioplasty); OR the 
neurological deficit results in death, c) no other  readily identifiable non -
stroke cause for the clinical presentation (e.g.,  brain tumor, trauma, 
infection, hypoglycemia, peripheral  lesion,  pharmacological influence), d) 
confirmation of the diagnosis by  at least one of the following: neurology or 
neurosurgical  specialist, neuroimaging procedure (MR or CT scan or 
cerebral  angiography), lumbar  puncture (i.e., spinal fluid analysis 
diagnostic or  intracranial  hemorrhage ). 
 
12.3.1.3  Vascular complications (e.g. clinically significant groin  hematoma,  
arteriovenous fistula, pseudoaneurysm, excessive bleeding)  requiring  
surgical repair, interventional procedu re, thrombin injection, or  blood  
transfusion (requiring more than 2 units of packed red blood  cells within 
any 24-hour period during the first 7 days post  procedure).  
 
12.3.1.4  Hypertensive crisis/emergency is defined as severely elevated  blood  
pressure, usually higher than 180/110 mm Hg, together  with progressive 
or impending target organ damage, requiring  in-patient  hospitalization and 
typically admission to the Intensive Care Unit  (e.g., with parenteral IV 
antihypertensive medications), not related  to confirmed non -adherence 
with medication.  
 
12.3.1.5  New renal artery stenosis defined as >70%, confirmed by  angiography.  
 
12.3.1.6  Cardiac damage due to any cause except pulmonary vein stenosis  or 
atrio-esophageal fistula and including MI [the presence of any one  of the 
following criteria: 1 -detection of ECG changes indicative of  new ischemia 
(new ST -T changes or new LBBB) which persist for  more than one hour; 
2-development of new pathological Q waves on  an ECG; 3 -imaging 
evidence of new loss of viable myocardium or  new regional wall motion  
abnormality ]. 
 
12.3.1.7  Pulmonary vein stenosis defined as >75% reduction in diameter of  the 
baseline pulmonary vein area on CT or  MRI.  
 
12.3.1.8  Atrio-esophageal  fistula defined as a connection between the  atrium  and 
the lumen of the esophagus. Evidence supporting this  diagnosis includes 
documentation of esophageal erosion combined  with evidence of a 
fistulous connection to the atrium such as air emboli,  an emboli c event, or 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 56 of 92   direct observation at the time of surgical repair.  A CT scan or MRI scan 
are the most common methods  of documentation of an atrial -esophageal  
fistula.  
 
12.3.1.9  Arrhythmia excludes atrial fibrillation and including creation of  new 
arrhythmias and/or worsening of existing  arrhythmias.  
 
12.3.1.10  Persistent phrenic nerve palsy defined as absent phrenic  nerve function 
as assessed by a sniff test or chest x -ray including  inspiration/expiration 
films. Persistent is defined as lasting 6  months or longer, or la sting until 
the last known follow -up if the follow -up is less than 6  months.  
 
12.3.2  Hypothesis  
There is no hypothesis for this  objective.  
 
12.3.3  Performance  Requirements  
Given the exploratory nature of a feasibility study, there is no  performance 
requirement for this objective. The rate of safety composite endpoints will  be 
characterized by estimating the rate within each arm and estimating  the difference in 
rate between arms. These event rate estimates will provide  critical guidance for 
designing a possible subsequent pivotal  study.  
 
12.3.4  Rationale for Performance  Criteria  
This primary safety endpoint is a composite that combines the safety  endpoints from 
current Medtronic hypertension and AF studies and is intended to  include  serious 
adverse events ass ociated with either the renal artery denervation  or cryoablation  
procedure.  
 
The safety composite event rate in the STOP -AF trial was 3.1% with a  one-sided  
upper 95% confidence bound of 6.3%. The safety composite event rate  in subjects 
undergoing renal art ery denervation using the first generation  Symplicity system 
(Symplicity Catheter and G2 Generator) in the Symplicity HTN -3 trial 1.4% (one -sided 
upper 95% confidence bound of 2.9% ).16 If undergoing  both pulmonary vein isolation 
and renal artery denervation procedures at once is  as safe as undergoing each 
procedure separately, then the proportion of  patients that would be expected to 
experience a composite safety event is  approximately 4.5% (based on observed 
rates) to 9 .2% (based on upper 95%  confidence bounds).  
 
A DMC will periodically review accumulating safety data for the study,  including  the 
rate of safety composite events within each study arm and the difference  in the rate 
between study  arms.  
 
12.3.5  Analysis Methods  
For computing the proportion of subjects in each arm that experience  safety 
composite events, Kaplan -Meier methods will be used. Since all components  of the 
safety composite event include events through 30 days and four  components include 
events through 6 mon ths post -procedure, there is the potential for  some subjects 
having incompletely assessed safety composite outcomes should  they discontinue 
study participation prior to 6 months of post -procedure  follow -up. 
Kaplan -Meier estimation uses the time that each subject is free from a  safety 
composite event, defined from the date of procedure to the earliest date that  an 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 57 of 92   event meeting one of the safety composite event component definitions  occurs. For 
events that are typically confirmed at a clinic visit (e.g . renal artery  stenosis 
confirmed with angiography), it can be difficult to determine the onset  date exactly. 
Therefore, events whose onset date is equal to a follow -up visit  date within the 6 -
month visit window will be treated as having occurred at 180  days  
post-procedure. All subjects that are event -free through a completed  6-month 
follow -up visit within the 6 -month visit window will be censored at 180  days.  
Otherwise, a subject’s event -free time will be from the date of procedure to  the latest 
follow -up visit. Treating safety composite event dates and censoring  dates  that occur at 
6-month visits within the 6 -month visit window as occurring  at 
exactly 180 days post -procedure prevents bias in the Kaplan -Meier  6-month estimate. 
The log -log transfor mation will be used to calculate a two -sided  95% confidence 
interval for the rate of safety composite events within each study  arm. 
 
The difference in event rate between arms will be estimated by the difference  in 
Kaplan -Meier estimates at 6 months. A 95% confidence interval for the  difference will 
be constructed by applying the delta method to the log -log transform of  the difference 
in the Kaplan -Meier  estimates.  
 
12.3.6  Determination of Patients/Data for  Analysis  
All randomized subjects in the modified intention -to-treat cohort will be included in the  
analysis.  
 
12.3.7  Sample  Size 
There are no sample size requirements for this  objective.  
 
12.4 Primary effectiveness  objective  
The primary effectiveness objective compares the rate of chronic  treatment s uccess 
between study arms. Chronic treatment success is freedom from  chronic treatment 
failure. Therefore, comparing the rate of chronic treatment success  is equivalent to 
comparing the risk of chronic treatment  failure.  
Chronic treatment failure is defined as the occurrence of  either  
1) a documented episode of AF recorded on Reveal  LINQ  
2) an intervention for  AF 
occurring after a blanked follow -up period of 90 days from the study  treatment  
procedure. AF episodes and repeat ablations that occur within 90 days of  the study 
treatment procedure will not constitute chronic treatment  failure.  
Intervention for AF is defined as an invasive procedure intended for the  definitive 
treatment of AF, including any ablation of the pulmonary veins or atrial  triggers (othe r 
than protocol -specified ablation), interruption of AV nodal  function, procedures to alter 
left atrial conduction or function such as the Maze  procedure,  or the implantation of an 
atrial pacemaker or atrial defibrillator; whether  approved  by relevant regu latory 
authorities or not for such indications; excluding electrical  or pharmacologic 
cardioversion of arrhythmias and excluding procedures  solely directed at the treatment 
of atrial flutter or atrial  tachycardias.  
 
12.4.1  Hypothesis  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 58 of 92   The primary effectiveness obj ective will be assessed with the  following  hypothesis:  
 
H0: hControl (t) = h Treatment (t) for all t ≤ T  years H A: 
hControl (t) ≠ h Treatment (t) for some t ≤ T  years  
where h(t) is the hazard function (risk) of chronic treatment failure and T is  the total 
study  time.  
 
12.4.2  Performance  Requirements  
If the hazard ratio for chronic treatment failure between the Treatment  and Control 
only arms is less than one and the two -sided log -rank p -value is  less 
than 0.05, it will be concluded that the pulmonary vein isolation and renal  artery 
denervation procedure results in a higher rate of chronic treatment  success.  
Given the feasibility nature of this study and relatively small sample size, even  if the 
pulmonary vein isolation and renal artery denervation procedure  results in  a clinically 
meaningful improvement in the rate of chronic treatment success  (e.g. an absolute 
10-15% higher chronic treatment success rate through 6  months), the log -rank test 
may not reach statistical significance  (p<0.05).  
This study is inte nded to provide data to support the design of a pivotal  trial. The 
estimates of the chronic treatment success rate for each study arm  can provide 
that data whether the log -rank test is statistically significant or  not. 
 
12.4.3  Rationale for Performance  Criteria  
In the STOP -AF trial, subjects randomized to receive cryoablation had a  6- month 
chronic treatment success rate of 75.0%. In the patient population  of this  feasibility 
study, including patients with either paroxysmal AF or  persistent  AF and with 
uncontrolled hypertension, the rate of chronic treatment success  is expected to be 
lower.  Also, use of intensive AF monitoring with the  Reveal  LINQ device has the 
potential to identify patients with recurrent AF that  might not be detected with 
periodic tr ans-telephonic and Holter monitoring, as  was performed in the STOP -AF 
trial, leading to a lower rate of chronic  treatment  success. In the treatment arm, the 
addition of the renal artery  denervation  procedure to the pulmonary vein isolation 
procedure for tr eatment of AF has  the potential to increase the rate of chronic 
treatment success. While it’s  uncertain  to what degree these factors may affect the 
rate of chronic treatment  success, this feasibility study is designed to be able to 
identify a difference in  chronic treatment success rate if the rate through 6 months is 
at least 75% in  the Treatment arm and 50% in the Control arm through 6  months.  
 
12.4.4  Analysis Methods  
A log -rank test will be used to perform this hypothesis test. The log -rank test uses 
the time t hat each subject is free from chronic treatment failure,  defined  from the 
date of procedure to the date of chronic treatment failure, if it  occurs, or latest of 
the following: a) the last follow -up visit date, or b) the last date  on which AF was 
assessed, if chronic treatment failure does not occur during  the subject’s study 
follow -up. Subjects will be included through all available  study  follow -up. 
In addition to the log -rank test, Kaplan -Meier curves will be used to estimate  the rate 
of chronic treatment success. Cox proportional hazards regression will  be used to 
estimate the hazard ratio and its 95% confidence interval  between  study  arms.  
 
12.4.5  Determination of Patients/Data for  Analysis  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 59 of 92   All randomized subjects in the modified intention -to-treat cohort will be included in the  
analysis.  
 
12.4.6  Sample  Size 
There will be at least 78% power to test this objective provided at least  70 subjects 
undergo  randomization.  
 
The sample size calculation is based on the following  assumptions:  
• 1:1 randomization  
• Constant randomization rate over 16  months  
• Last enrolled subject followed through 6 months  post-procedure  
• 50% chronic treatment success in the PVI only arm versus 75% in  the 
Treatment arm (equivalent to a hazard rat io of 0.415) through 6  months 
post-procedure  
• Constant hazard ratio over all  follow -up 
• Cumulative alpha of 0.05 .  Any planned interim analyses will be constructed 
so that the overall Type I error of the study is no greater than 0.05.  
• Constant attrition (dropout) of 5% per 6  months  
 
The sample size calculation was performed in PASS 2008 using the  log-rank 
(Lakatos) procedure. Accounting for a study attrition rate of up to 5% per  6 months 
ensures that the study will maintain the planned power of 78% in case attrition is 
higher than expected (approximately 1% per 6  months).  
 
12.5 Secondary  objective  
 
12.5.1  Single Procedure Chronic Treatment  Success  
The secondary effectiveness objective charact erizes the rate of  chronic treatment 
success in Treatment and Control arms in the subgroup of  subjects that do not 
undergo an additional pulmonary vein ablation procedure during  the 90-day blanked 
follow -up period.  
 
12.5.2  Hypothesis  
There is no hypothesis for this  objective.  
 
12.5.3  Performance  Requirements  
There is no performance requirement for this  objective.  
 
12.5.4  Analysis Methods  
Kaplan -Meier curves will be used to estimate the rate of chronic  treatment success 
for each study arm. Cox proportional hazards regression will be  used  to estimate 
the hazard ratio and its 95% confidence interval between  study  arms.  
 
12.5.5  Determination of Patients/Data for  Analysis  
All randomized subjects in the modified intention -to-treat cohort  that do not undergo  
a permissible repeat  cryoablation  will be included in the  analysis.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 60 of 92    
12.6 Ancillary  objectives  
The ancillary objective endpoints below will be compared between study arms  in order 
to further characterize the differences in outcomes between  patients randomized to 
pulmonary vein isolation only to those randomized to  pulmonary vein isolation and 
renal artery denervation. Mean, standard deviation, median,  and range will be used as 
descriptive statistics for continuous variables and counts and  proportions  for 
categorical variables. An ANCOVA model will be used  to compare the mean change in 
continuous variables from baseline to 6  months  
between the study arms. The ANCOVA model will include change  measurement  (e.g. 
heart rate, blood pressure) from baseline t o the 6-month  follow -up visit as  the 
response and study arm indicator and baseline measurement as covariates.  For the 
symptoms ancillary objective, a logistic regression model will model  presence of each 
symptom at 6 months as the response and study arm in dicator  and baseline presence 
of symptom as covariates. For the freedom from  chronic treatment failure off anti -
arrhythmic drugs objective, a log -rank test over  all available follow -up will be 
performed. For the AF burden objective, the  Mann - Whitney U tes t will be used to 
compare the AF burden between study arms.  This non -parametric test is used rather 
than the Student’s t -test since AF burden  tends  to have a skew distribution with many 
values near zero. The difference in  AF burden will be characterized by  the Hodges -
Lehmann estimator, the median of  all pairwise differences in AF burden between study  
arms.  
• Office systolic and diastolic blood pressure at 6 months compared  to 
baseline  
• Heart rate at 6 months compared to  baseline  
• Procedural measures (total procedure time, cryoablation  procedure time, 
renal artery denervation procedure time, ablation time,  fluoroscopy  time, dye  
usage)  
• Symptoms at 6 months compared to  baseline  
• Freedom from chronic treatment failure and off Class I and III  anti- 
arrhythm ic drugs following the blanking  period  
• AF burden (percent of time in AF) over all follow -up after the  blanking 
period  
 
12.7 Subgroup  analysis  
To characterize the consistency of the estimated treatment effect across  AF diagnoses 
(paroxysmal or persistent AF), a score test will be performed on  the interaction term in a 
Cox proportional hazards regression with study arm  indicator, AF diagnosis, and 
interaction between study arm and AF diagnosis as  factors.  
Similar sub -group analyses, assessing the  interaction term in a regression  model, will 
be performed for the secondary and ancillary objectives. In addition to  the subgroup 
analysis by AF diagnosis, a subgroup analysis using the  same methodology will be 
performed to characterize the consistency of  the estimated  treatment effect across 
patients who received touch -up ablations to complete  the electrical isolation of one or 
more pulmonary veins with an RF catheter  versus  those whose pulmonary veins were 
treated only with  cryoablation.  
 
12.8 Interim  analysi s 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 61 of 92   Interim analyses will be performed .  
Two interim analysis of the primary effectiveness objective may be performed after 
32 and 50 subjects have been randomized and completed their 6 -month follow -up 
visits , respectively . Both the sponsor and the DMC will assess the results of the 
interim analys es of the primary effectiveness objective  and based on this 
assessment, the sponsor may decide to stop enrollment .  
 
Time Point of Interim Analyses of the 
Primary Effectiveness Objective  Cumulative 
Alpha  Boundary * Pass/Fail Primary 
Effectiveness Objective  
After 32 subjects were randomized 
and completed their 6 -month visit  0.01 0.01 If a two -sided p -value ≤ 0.01, 
in favor of the treatment 
group, then the study passed 
the primary effectiveness 
objective  
After 50 subjects were randomized 
and completed their 6 -month visit  0.015  0.008  If a two -sided p -value ≤ 
0.008,  in favor of the 
treatment group, then the 
study passed the primary 
effectiveness objective  
Final Analysis:  
After 70 subjects were randomized 
and completed their 6 -month visit  0.05 0.04 If a two -sided p -value ≤ 0.04, 
in favor of the treatment 
group, then the study passed 
the primary effectiveness 
objective  
*Boundaries were calculated using EAST 6.4.1  
 
In addition to reviewing the effectiveness data from the interim analyses, t he DMC 
will be responsible  for assessing the accumulating data on safety of the procedures 
during the  study. The primary responsibility of the DMC is to safeguard  the interests 
of study  participants. The DMC also monitors the overall conduct of the clinical  study. 
Further information regarding the DMC is found in Appendix C: Data  Monitoring  
Committee . 
 
12.9 Pooling of study centers for analysis  
 
Data from study centers will be pooled for analysis. Descriptive statistics of endpoints 
may be performed for groups of centers based on regional criteria. However, no 
statistical analysis will be performed to test center variation for the primary effectiveness 
objective. The study is expected to be conducted at up to 12 centers located in the 
United  States and up to three centers in Europe with a total of 70 randomized subjects in 
the modified -intent -to-treat cohort. Given the small sample size, a formal test of 
interaction between randomization group and center will likely not be powered to detect 
a statistically significant difference for the primary endpoint if one exists. Likewise, the 
small sample size may not allow the use of a model adjusting for center as a random 
effect.  
 
12.10  Missing  data 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 62 of 92   Sensitivity analyses will be conducted to assess the robus tness of the  primary 
analyses to missing data should the issue of missing data arise in the  study. 
Sensitivity analyses include, but are not limited to , tipping point  analyses.  
 
13. DATA AND QUALITY  MANAGEMENT  
Data will be collected using an electronic data management system for clinical  
studies. CRF data will be stored in a secure, password -protected database which will 
be backed  up nightly. Data will be reviewed using programmed and manual data 
checks.  Data queries will be made available to centers for resolution. Study 
management reports  may be generated to monitor data quality and study progress.  
At the end of the study,  the data will be frozen and will be retained indefinitely by  
Medtronic.  
The data reported on the CRFs shall  be derived from source documents and  be 
consistent with these source documents, and any discrepancies shall be explained  in 
writing.  
The sponsor or regulatory bodies  may audit the study center to evaluate the conduct 
of the  study. The clinical investigato r(s)/institution(s) shall allow study related 
monitoring, audits,  IRB/MEC  review and regulatory inspection by providing direct 
access to source  data/documents.  
 
14. WARRANTY/INSURANCE  INFORMATION  
Warranty information is provided in the product packaging. Addit ional copies  are 
available upon  request.  
 
Insurance (US)  
Medtronic Inc. maintains appropriate clinical study liability insurance coverage as 
required under applicable  laws and regulations and will comply with applicable law and 
custom concerning specific insurance coverage.  If required, a Clinical Trial Insurance 
statement/certificate will be provided to the IRB.  The study is conducted in multiple 
countries, therefore , reimbursement and indemnification will be addressed  on a country 
specific basis  in the study documents and center Clinical Trial Agreements.  
 
Insurance (Europe)  
Medtronic Bakken Research Center B.V. is a wholly owned subsidiary of Medtronic, Inc., 
which as the parent  company of such entity maintains appropriate clinical study liability 
insurance coverage as required under  applicable laws and regulations and will comply 
with applicable local law and custom concerning specific  insurance coverage. If required, 
a Clinical Trial insurance statement/certificate will be provided to th e Ethics  Committee.  
 
15. MONITORING  
It is the responsibility of Medtronic to ensure proper monitoring of this  clinical 
investigation per regulations. Trained Medtronic personnel or delegates appointed  by 
Medtronic may perform study monitoring at the study cent er in order to ensure that  
the study is conducted in accordance with the CIP, the Clinical Trial Agreement,  and 
applicable regulatory and local requirements. Medtronic, or delegates, must  
therefore be allowed access to the subjects’ case histories (clinic and hospital 
records, and  other source data/documentation) upon request as per the Consent 
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 63 of 92   Form,  Privacy Authorization, Research Authorization (where applicable) and Clinical 
Trial Agreement.  
 
15.1 Monitoring  visits 
Frequency of monitoring visits will b e based upon subject enrollment, duration  
of the study, study compliance, number of adverse events, findings from  
previous  monitoring visits and any suspected inconsistency in data that  
requires  investigation.  Regulatory documents may be reviewed at each study  
center.  
 
Monitoring for the study will be done in accordance to the Medtronic internal 
study monitoring  plan.  
Monitoring visits may be conducted periodically to assess center study  
progress, the investigator’s adherence to the CIP, regulatory complia nce 
including but  not limited to IRB /MEC  approval and review of the study, 
maintenance of records  and reports, and review of source documents against 
subject CRFs  (source verification).  
 
When source data verification is performed, the monitor must have direct  
access to original source documentation or certified copies of the original 
source must  be provided.  
If electronic source documentation is used at the site, the site must provide to  
the monitor:  
1) Direct access to the electronic medical record (e.g. the monitor is given a  
guest password to directly access the syste m) or 
2) Direct access to the electronic medical record by reviewing  
alongside  appropriate study staff (e.g. a research coordinator)  or 
3) Certified copies of the electronic medical record. The site shall  provide  
adequate documentation to the monitor describing their process for  
providing  complete and accurate certified copies for required source  
documentation.  
The monitor shall verify that he/she has complete access to all original  source 
documentation required for the study (e.g. the monitor does not have a lower  
level of access to the original source documentation than the research 
coordinator  or Principal Investigator necessary for the  study).  
Monitors review center regulatory and  study compliance by identifying findings  
of non -compliance and communicating those findings along with  
recommendations  for preventative/corrective actions to center personnel. 
Monitors may work  with study personnel to determine appropriate corrective 
action recommendations  and to identify trends within the study or at a 
particular  center.  
 
16. REQUIRED RECORDS AND  REPORTS  
16.1 Investigator  records  
The investigator is responsible for the preparation and retention of the  records  
cited below. All of the below records, with the exception of case history  records  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 64 of 92   and CRFs, should be kept in the Investigator Center File (i.e., the study  binder  
provided to the investigator) or Subject Study Binder. CRFs may be  maintained  
and signed electronically within the electron ic data capture system during  the 
study. The following records are subject to inspection and must be retained for  
a period of two years (or longer as local law or hospital administration requires)  
after the investigation is  terminated.  
• All correspondence between the IRB /MEC , sponsor, monitor, regulatory 
bodies  and/or  the investigator that pertains to the investigation, including 
required  reports.  
• Subject’s case history records,  including:  
o Signed and dated informed consent form signed by  subject 
o Observations of adverse events and device  deficiencies  
o Medical  history  
o Procedure and follow -up data 
o Documentation of the dates and rationale for any deviation from  
the protocol  
o Electronically signed and dated  CRFs  
o Device disposition  records  
• All approved versions of the  CIP 
• Report of Prior  Investigations  
• Executed Clinical Trial Agreement  
• Curriculum vitae for each  investigator  
• Delegated task  list 
• IRB/MEC  approval documentation. Written information that the investigator  
or other study staff, when a member of the IRB /MEC , did not participate in  
the approval process. IRB /MEC  approval of the current version of the CIP  
and Informed Consent Form and acknowledgment of the Report of  Prior  
Investigations.  
• Study training records for center  staff 
• Financial  disclosure  
• Any other records that regulatory bodies require to be  maintained  
• Final Study Report including the statistical  analysis  
• Any other regulatory authority or required records  
 
16.2 Investigator  reports  
The investigator is responsible for the preparation (review and signature)  and 
submission to the sponsor of all CRFs, AEs and device deficiencies, deaths,  and any 
deviations from the CIP. If any action is taken by an IRB /MEC  with respect to  this 
clinical study, copies of all pertinent documentat ion must be forwarded  to Medtronic in 
a timely manner. Reports are subject to inspection and to  the retention requirements 
as described above for investigator  records.  
Safety data investigator reporting requirements are listed in Section 9 of the  Adverse 
Event section. The investigator shall prepare and submit in a complete,  accurate and 
timely manner the reports listed in this  section.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 65 of 92    
Table 1 2: Investigator reports  
Report  Submit to  Description/Constraints   
Withdrawal of  
IRB/MEC  
approval  
(either 
suspension or 
termination)  Sponsor  and 
Relevant 
Authorities  US: The investigator must report a withdrawal of approval  by 
the reviewing IRB /MEC  of the investigator’s part of  the 
investigation within 5 working days. (21 CFR 812.150(a)(2))  
Europe: Report if required by local law.  
 
Progress  report   
Sponsor and  
IRB/MEC  US: The investigator must submit this report to the sponsor  and 
IRB/MEC  at regular intervals, but in no event less than  yearly. (21 
CFR 812.150  (3)). 
Europe:  Provide if required by local law or IRB/MEC.  
 
 
 
 
 
Study  deviations   
 
 
 
 
Sponsor and  
IRB/MEC  US: Notice of deviations from the CIP to protect the life  or physical 
well-being of a subject in an emergency shall  be given as soon as 
possible, but no later than 5 working  days after the emergency 
occurred. Except in such  emergency, prior approval is required for 
changes in the plan  or deviations. If the deviation may affect the  
scientific soundness of the plan or the rights, safety and welfare  of 
the subjects, the deviation must be approved by  Medtronic, the 
IRB/MEC , and the FDA/applicable regulatory authorities.  If the 
deviation does not affect these iss ues then  only Medtronic must 
approve it.  (21 CFR  812.150(a)(4))  
Europe:  Any deviation from the CIP shall be recorded together 
with an explanation for the deviation. Deviations shall be reported 
to the sponsor who is responsible for analyzing them and 
asse ssing their significance.  
Note: When relevant, ethics committees, competent authorities or 
the appropriate regulatory bodies should be informed.  
Failure to  obtain 
informed  consent 
prior to 
investigational 
device  use  
Sponsor and  
IRB/MEC  US: If an investigator uses a device without obtaining  informed 
consent, the investigator shall report such use within  5 working 
days after device use.  (21 CFR  812.150(a)(5))  
Europe: Informed consent shall be obtained in writing and 
documented before a subject is e nrolled into the clinical 
investigation.  
Final  report  Sponsor  and 
IRB/MECs  All geographies: This report must be submitted within 3 months of  
study completion or termination of the investigation or  the 
investigator’s part of the investigation. (21 CFR 812.150(a)(6))  
Other  IRB/MEC and  
FDA US: An investigator shall, upon request by a reviewing  IRB/MEC, 
FDA or any other regulatory agency, provide  accurate, complete, 
and current information about any aspect of  the investigation. (21 
CFR 812.150(a)(7))  
 
 
 
16.3 Sponsor  records  
Medtronic shall maintain the following accurate, complete, and current  records:  
• All correspondence which pertains to the  investigation  
• Investigational device traceability record containing model and  serial  
numbers of devices, shipping date and name and address of person  that 
received shipped device, location (if different than person shipped  to), 
transfer and receipt by Medtronic  dates  
• Signed and dated Confidential Disclosure Agre ements or documentation  of a 
Master  Agreement  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 66 of 92   • Executed Clinical Trial Agreements, financial disclosure, curriculum vitae  of 
each investigator and delegated task  list 
• All signed and dated CRFs submitted by investigator, including reports  of 
AEs, and device deficiencies, and CRF  corrections  
• Samples of informed consents, and other information provided to  the 
subjects, including translations (if  applicable)  
• Copies of all IRB /MEC  approval letters and relevant IRB /MEC  
correspondence  and IRB/MEC  voting list/roster/letter of  assurance  
• Names of the institutions in which the clinical investigation will  be 
conducted  
• Names/contact addresses of  monitors  
• Statistical analyses and underlying supporting  data 
• Final Report of the clinical  investigation  
• The C IP, CRFs, Report of Prior Investigations and study related  reports, and  
revisions  
• Study training records for center personnel and Medtronic  personnel  
involved in the  study  
• Any other records that local regulatory agencies require to be  maintained  
 
16.4 Sponsor  reports  
Medtronic shall prepare and submit the following complete, accurate, and  timely reports 
listed in the tables below. In addition to the reports listed below,  Medtronic shall, upon 
request of reviewing IRB /MEC  and regulatory bodies , provide accurate, complete  and 
current information about any aspect of the investigation. Safety data  Medtronic reporting 
requirements are listed in Table 9 of the Adverse Event  section.  
 
Table 1 3: Sponsor  reports  
Report  Subm it to Description/Constraints 
  
Withdrawal of  IRB/MEC  
approval  Investigators, 
IRB/MEC , and  FDA US: Notification within five working days. 
(21 CFR 812.150(b)(2))  
Premature termination or 
suspension of the clinical 
investigation  Investigators, IRB/MEC, 
Relevant authorities and 
Head of the Institution  Europe: Provide prompt notification of 
termination or suspension and reason(s). 
(ISO 14155:2011)  
Withdrawal of  FDA 
approval  Investigators  and 
IRB/MEC  US: Notification within five working days. 
(21 CFR 812.150(b)(3))  
Withdrawal of CA 
approval  Investigators, Head of 
Institution, IRB/MEC, and 
relevant authorities  Europe: Investigators, IRBs/MECs will 
be notified only if required by local laws 
or by the IRB/ME C. 
 
Investigator  List  
FDA US: Submit at 6 -month intervals, a current list of the 
names  and addresses of all investigators participating 
in the investigation.  (21 CFR  812.150(b)(4))  
Progress  Reports  IRB/MEC  and FDA US: Progress reports will be submitted at least 
annually.  (21 CFR 812.150(b)(4)(5),  812.36(f)  
Europe:  This will be submitted to the IRB/MEC only 
if required by the IRB/MEC.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 67 of 92   Report  Subm it to Description/Constraints 
   
Recall and  device 
disposition   
Investigators,  IRB/MEC  
and FDA US: Notification within 30 working days and will 
include  the reasons for any request that an 
investigator return,  repair, or otherwise dispose of 
any devices. (21 CFR 812.150(b)(6))  
Failure to  obtain 
informed  consent  FDA US: Investigator’s report will be submitted to FDA 
within  five working days of notification.  (21 CFR  
812.150(b)(8))  
 
 
Final  report   
Investigators,  IRB/MEC  
and FDA  US: Medtronic will notify FDA within 30 working days 
of the completion or termination of the investigation. A 
final report will be submitted to the FDA, investigators, 
and IRB /MEC s within six months after completion or 
termination of this  study.  
(21 CFR  812.150(b)(7))  
 
Study  deviation   
Investigators  US: Ensure that all deviations from the Clinical  
Investigation Plan are reviewed with the appropriate  
clinical investigator(s), are reported on the case 
report forms  and the final report of the clinical  
investigation.  
Europe:  Ensure that all deviations from the Clinical 
Investigation Plan are reviewed with the appropriate 
clinical Investigator(s), are reported on the case 
report forms and the final report of the clinical 
investigation.  
 
Center specific study deviations will be  submitted to 
Investigators periodically.  
 
Other   
IRB/MEC , FDA US: Accurate, complete, and current information 
about  any aspect of the clinical investigation. (21  
CFR 812.150(b)(10))  
 
Medtronic records and reports will be maintained in a  password -protected  document 
management system, and paper documents (where applicable) will  be stored in stored 
in secured file cabinets at Medtronic during the course of  this study.  
 
After closure of the study Medtronic will archive records and reports  indefinitely.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 68 of 92   APPENDIX A: DRAFT DATA COLLECTION  ELEMENTS  
Final CRFs will be provided to centers via the electronic data management system  after 
the center has fulfilled all requirements for database  access.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 69 of 92   APPENDIX B: PRELIMINARY PUB LICATION  PLAN  
Publications from the Symplicity AF will be handled according to the  Clinical 
Investigation Plan, Medtronic procedures and as indicated in the Clinical  Trial 
Agreement.  
 
Publication Committee  
Medtronic may form the Symplicity AF Publication Committee from study  investigators. 
Medtronic personnel may serve as members of the committee. This committee  will 
manage study publications with the goal of publishing findings from the data.  The 
Publication Committee will develop the final Pu blication Plan as a separate  document.  
The Publication Committee’s role is to: 1) manage elements addressed in the  publication  
plan as outlined in this appendix, 2) develop the final Publication Plan under  separate 
cover, 3) execute the Publication Plan, 4 ) oversee the publication of primary,  secondary 
and ancillary study results, 5) review and prioritize publication proposals, 6) provide  input  
on publication content, and 7) determine authorship.  In addition, the committee  will 
apply and reinforce the auth orship guidelines set forth in the Publication  Plan.  
Membership in the Publication Committee does not guarantee authorship.  The 
committee will meet at regular  intervals.  
 
Management of Primary, Secondary and Ancillary Publications  
The Publication Committee  reviews, prioritizes and manages all publications  including  
primary, secondary and ancillary publications. Primary and secondary publications  are 
those that address analyses of any or all primary objectives or secondary  objectives, 
respectively, as specified in the Clinical Investigation  Plan.  
An ancillary publication is any publication that does not address the study  objectives  
identified in the Clinical Investigation Plan. They include publications proposed  and 
developed by other M edtronic departments or entities, clinicians participating in  this 
clinical study and clinicians not participating in this clinical study. The committee  will 
work with Medtronic to ensure that requests do not present conflicts with  other  
proposals, are not  duplicative and to determine which ancillary publication proposals,  if 
any, will be  supported.  
The committee may decide that no publications, including abstracts, will be  published  
prior to the end of the study or with individual center data. Requests for  publications  on 
study objectives utilizing subset data will be evaluated for scientific validity and the  ability 
of Medtronic to provide  resources.  
 
Criteria for Determining Authorship  
Publications will adhere to authorship criteria defined by the International Committee  of 
Medical Journal Editors (ICMJE, Uniform requirements for manuscripts submitted  to 
biomedical journals, www.icmje.org). Individual authorship criteria defined by the  target 
journal or conference will be followed when it differs fr om ICMJE  criteria.  
Authors, including Medtronic personnel, must at a minimum meet all of the  conditions  
below:  
• Substantial contribution to conception and design, or acquisition of data,  or 
analysis and interpretation of  data 
• Drafting the article or revising it critically for important intellectual  content  
• Final approval of the version to be  published  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 70 of 92   Decisions regarding authorship and contributor -ship will be made by the committee.  The 
selected authors will be responsible for drafting t he publication. All selected  authors 
must fulfill the authorship conditions stated above to be listed as authors, and  all 
contributors who fulfill the conditions must be listed as  authors.  
All investigators not listed as co -authors will be acknowledged as the “Medtronic 
Symplicity AF Clinical Study Investigators” and will be individually listed according to  the 
guidelines of the applicable scientific journal when possible. Any other contributors  will 
be acknowledged by name with their specific contribution  indicated.  
 
Transparency  
Transparency of study results will be maintained by the following  means:  
• a Final Report, describing the results of all objectives and analysis, will  be 
distributed to all investigators and  IRB/MEC s 
• registering and post ing the study results on ClinicalTrials.gov based on  the 
posting rules  stipulated  
• submitting for publication the primary study results after the study  ends  
• disclosing financial interests of the co -authors of publications according  to 
the policies set forth by the corresponding journals and  conferences  
• making an individual centers study data accessible to the  corresponding 
investigator after the completion of the study, if  requested  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 71 of 92   APPENDIX C: DATA MONITORING  COMMITTEE  
Ongoing oversight for this study will be provided by an independent DMC. The DMC  will 
have one statistician, and at least two physicians specializing in either cardiac  ablation,  
renal denervation, managing atrial fibrillation and/or managing blood pressure. None  of 
the DMC members are participating in the Symplicity AF study. A chairperson  from 
among those members has been identified. A DMC charter has been approved by  the 
members.  
The DMC will be responsible for assessing the primary effectiveness data as well as 
accumulating data on safety of  the procedures during the study. The DMC will be 
responsible for safeguarding the  interests of study participants and for monitoring the 
overall conduct of the clinical study.  To enhance the integrity of the study, the DMC ma y 
also formulate  recommendations  related to the selection, recruitment, and retention of 
subjects, their  management, improvement of adherence to protocol -specified regimens 
and procedures for  data management and quality control.  The DMC may also provide 
recommendations  for early termination of the study for the safety of study  participants.  
Analyses of the study objectives for review by the DMC will be performed by a  Medtronic 
statistician other than the lead statistician for the study. The lead study statistician will  be 
blinded to all DMC analyses of study objectives. The unblinded statisticians will  keep 
results strictly confidential per the DMC charter during the  study.  
Version 18 19AUG2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 72 of 92   APPENDIX D: INFORMED CONSENT  TEMPLATES  
The informed c onsent template will be distributed under separate  cover .
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 73 of 92    
APPENDIX E: PARTICIPATING INVESTIGATORS, 
INSTITUTIONS AND  IRB/MEC S 
A complete list of  participating investigators, institutions and IRB /MEC s where study activities 
will be conducted will be distributed under  a separate cover when  available.  
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 74 of 92 
8179   APPENDIX F:  LABELING  
Labeling for all system components can be found with each package insert.  The 
Symplicity Spyral Catheter and the Symplicity G3 Generator will be  labeled 
investigational  in the United States . Labeling of CE marked devices follows local 
language requirements.  
The Arctic Front Advance , Arctic Front Advance Pro,  Freezor MAX  and the Reveal LINQ 
System will not be labeled  as investigational  in the United States . Commercially available 
product will be used for the  study  in all geographies . 
 
 
  
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 75 of 92 
8179   APPENDIX G: BLOOD PRESSURE  MEASUREMENT  
PROCEDURES  
 
1. Office blood  pressure  
 
All office blood pressure (OBP) measurements must be taken with the automatic  BP 
Monitor and printer provided by  Medtronic.  
 
All attempts should be made to measure the subjects BP within the same  approximate 
timeframe of the day (i.e., morning, afternoon, or  evening).  
 
A. Arm selection  
1. With the subject prepped for “Preparation” section below, measure BP  in 
each arm. Print and label each  measure.  
2. Use the arm with the higher BP for screening measurements and  all 
subsequent measurements. If there is a reason to use a particular  arm, 
document the reason and use that arm for all  measurements.  
 
B. Preparation at all  visits  
1. Confirm the subject has taken all indicated anti -hypertensive  medications  
prior to the  measurements.  
2. Ensure the Date and Time has been set on the automatic BP Monitor  and 
confirm the printer, if available, is  operational.  
3. Confirm the subject did not drink coffee or alcohol, smoke or exercise  within 
30 minutes prior to the  measurement.  
4. Request the subject to use the bathroom prior to measurements (a  full 
bladder can affect the  reading).  
5. The subject should be seated comfortably with the back supported and  the 
upper arm bared without constrictive clothing. The legs should not  be 
crossed.  
6. Ensure the BP cuff is appropriately sized (see below) and the upper arm  is 
supported at the level of the heart (e.g. resting on a table at the level  of 
his/her  heart).  
 
Table 1 4: Cuff size  chart  
 
Cuff size*  Fits arm  circumference 
of (inches)  
Small  7-9 
Medium  9-13 
Large  13-17 
Extra  Large**  17-20 
*Opt for the larger of the two sizes if a subject is on the border  of two cuff  sizes.  
**Subjects requiring greater than an extra -large cuff size at time of the screening  must 
be excluded from the  study.  
 
7. Perform a “test” BP measure. Print (if available) and label the  measure.  
8. Have the subject sit comfortable and quietly for 5 minutes, with  back 
supported and feet flat on the ground (i.e. not on an exam table, legs  not 
crossed).  
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 76 of 92 
8179   C. Method for taking BP at all  visits  
1. With subject prepped for “Preparation” section above and using arm  selected  
at Screening, take at least three seated BP measurements in order to  obtain  
the BP  average.  
a. Wait at least 1 minute between each measurement. Ensure the  BP 
monitor time clock is used for tracking the time  intervals.  
b. Print (if available) and label after each  measurement.  
2. Three consecutive, consistent seated BP measurements must be  obtained 
for the BP  average.  
a. If the lowest and highest systolic BP vales of 3  consecutive 
measurements are more than 15 mmHg apart, take one  additional  
reading and average the last 3 consecutive  measurements 
(measurements 2 -4). If the measurements are still more than  15 
mmHg apart, take one additional reading and average the last  3 
consecutive measurements (measurements (3 -5). If more than  15 
mmHg apart, continue to the sixth and final  measurement.  
b. If less than a 15 mmHg difference cannot be obtained after at least  6 
documented measurements, a 20 mmHg d ifference will be  acceptable.  
c. At Screening: if the lowest and highest systolic BP values for  the 
readings are more than 20 mmHg apart after 6 measurements,  the 
subject must be excluded from the  study.  
3. Record the last 3 consecutive, consistent readings for the case report  form 
(do not pick the “best”  3). 
  
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 77 of 92 
8179   APPENDIX H: BIBLIOGRAPHY AND PRECLINICAL  AND  
CLINICAL  INVESTIGATIONS  
A complete bibliography, summary of relevant literature, summary and results  of 
preclinical testing and summary and results of previous clinical investigational  is 
provided in the Report of Prior  Investigations.  
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 78 of 92 
8179   APPENDIX I: MODIFICATIONS TO THE CLINICAL  
INVESTIGATION  PLAN  
Table 15  summarizes modifications made from previous version of CIP to the  current  
version of  CIP. 
 
Table 1 5: CIP change  history  
 
Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
1.0 Not applicable  Not applicable  First release  0 
2.0  
1.1 Added a possible  proposed 
indication should  Medtronic 
choose to study this  further.  Per recommendation 
from FDA 0 
2.0 1.2, 12.1,  12.4.6  Sample size updated to  include 
attrition  Per recommendation 
from FDA 0 
2.0  
 
 
 
 
 
 
 
 
5.2 Updated inclusion  criteria: 
Office -based systolic  blood  
pressure of ≥150 mm Hg  based 
on average of three  blood 
pressure readings despite 
treatment with 2 or  more 
antihypertensive medications  of 
different classes (one of  these 
must be a diuretic) at  maximum 
tolerated dose, highest  tolerated 
dose, or highest  appropriate 
dose for the patient per  Principal 
Investigator’s best  clinical 
judgment.  The subject  should 
be on a stable  antihypertensive 
drug regimen with no  changes 
for a minimum of 2 weeks  prior 
to enrollment and expected  to 
be maintained on that  regimen 
for at least 6  months.   
 
 
 
 
 
 
 
 
Per recommendation 
from FDA 0 
2.0  
5.1, 12.3 Change to primary  safety 
objective to compare rate  of 
safety composite  between 
treatment and control  subjects.   
Per recommendation 
from FDA 0 
2.0  
 
 
12.5  
 
Changed Secondary  Objective 
to Single Procedure  Chronic 
Treatment  Success  Adding the  new 
secondary was  per 
recommendation  from 
FDA. The  previous 
secondary became  the 
new primary  safety 
objective.  0 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 79 of 92 
8179    
Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
2.0  
 
 
 
 
5.1, 12.6 Added two new  ancillary 
objectives:  
• Freedom from atrial  
tachyarrhythmias 
(including AF, atrial  flutter 
and atrial tachycardia)  of 
30 seconds or  longer  
• Chronic treatment  Success 
off Class I and III  anti- 
arrhythmic drugs  following 
the blanking  period   
 
 
 
 
Per recommendation 
from FDA 0 
2.0  
5.2.1  Defined drug refractory as:  failed  
(drug is   ineffective  or  patient     
is  intolerant)  at  least  one     
Class I or III anti -arrhythmic  drug  
Per recommendation 
from FDA 0 
2.0 5.2.2, 6.4  (Table  
4), 6.7  Added requirement for TEE  and 
exclusion of subjects  when 
indicated  Per recommendation 
from FDA 0 
 
2.0  
5.2.2  Added exclusion: NYHA  Class 
IV heart failure with in the past  6 
months  Per recommendation 
from FDA 0 
 
 
 
2.0  
 
 
5.2.2  Updated exclusion in  include 
hyperaldosteronism: 
Pheochromocytoma,  Cushing’s 
Disease (adrenal  insufficiency), 
coarctation of the  aorta, 
untreated  hyperthyroidism, 
primary hyperparathyroidism  or 
hyperaldosteronism   
 
 
Per recommendation 
from FDA 0 
2.0 5.3, 6.11 Clarified randomization  strategy 
and process  Per recommendation 
from FDA 0 
2.0 5.4, 12.7, 
APPENDIX  C Clarified interim analysis  plans 
and DMC  responsibility  Per recommendation 
from FDA 0 
 
 
 
 
2.0  
 
 
6.4, 6.16.1,  6.16.2,  
6.20 TTM:  
 
Weekly TTMs added  between 
90 days and 12 Months  post 
ablation  procedure  
 
Updated symptomatic TTM  to 
start after blanking  period 
concurrent with weekly  TTMs   
 
 
Per recommendation 
from FDA 0 
 
 
 
2.0  
 
 
6.8 Added additional  detail 
concerning the  cryoablation 
procedure, including  Phrenic 
nerve monitoring,  anti- 
coagulation, procedure  steps, 
clarification of other  ablations, 
clarification of  procedure 
documentation.   
 
 
Per recommendation 
from FDA 0 
 
2.0  
6.9, 6.14 Details on peri and  post- 
procedural  anticoagulation 
including target  ACT.  Per recommendation 
from FDA 0 
 
 
 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 80 of 92 
8179   Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
 
2.0  
6.15 Updated Follow -up visit  windows 
to correct 18 and 24  months 
windows and add 30  month   
Correction  0 
 
2.0  
10 Risk Analysis: added  additional 
risks possible for  the 
cryoablation  procedure  Per recommendation 
from FDA 0 
2.0 12.3 Added definitions to some of  the 
safety composite  events  Per recommendation 
from FDA 0 
2.0 12.2, 12.6  Various  Typographical errors,  omissions 
and clarifications  Clarity  0 
 
3.0  
1.1 Modified a possible  proposed 
indication should  Medtronic 
choose to study this  further  Per recommendation 
from FDA 0 
 
3.0  
5.2.1  Inclusion criteria updated  to 
include definition of full  dose 
anti-hypertensive  medication  Per recommendation 
from FDA 0 
3.0 5.2.2  Removed adrenal  insufficiency 
from the exclusion  criteria  Per recommendation 
from FDA 0 
 
3.0  
6.6 Added definition of full dose  of 
anti-hypertensive  medication 
and stated it must  be 
documented   
Per recommendation 
from FDA 0 
 
 
 
3.0  
 
 
6.8.2  Added PVI endpoint  definition: 
After one or  more 
cryoapplications,  each 
pulmonary vein should  be 
minimally assessed for  entrance 
block and, where  assessable, 
exit block to demonstrate  the 
endpoint of electrical  isolation.   
 
 
Per recommendation 
from FDA 0 
 
3.0  
6.8.5  Clarified that  demonstrated 
electrical block is collected  on 
the case report  form Per recommendation 
from FDA 0 
3.0 6.14 Added post  procedure 
anticoagulation  instructions  Per recommendation 
from FDA 0 
 
3.0  
12.3 Removed definitions in Table  10 
and added a new section  that 
provides further  details 
regarding the safety  events   
Per recommendation 
from FDA 0 
 
 
 
 
3.0  
 
 
 
12.6 Clarified the ancillary  objective 
Freedom from  atrial  
tachyarrhythmias (including  AF, 
atrial flutter and  atrial  
tachycardia) of 30 seconds  or 
longer and off Class I and  III 
anti-arrhythmic drugs  following 
the blanking  period   
 
 
Per recommendation 
from FDA 0 
4.0 6.6 Clarified definition of  anti- 
hypertensive medication  dosing  Correction  0 
5.0 12.3.1.2,  12.3.1.8,  
12.3.1.10  Clarified safety event  definitions  Per recommendation 
from FDA 0 
 
 
 
 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 81 of 92 
8179    
Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
 
6.0  
1.1, 5.1.2,  5.2.1  Inclusion of patients  with 
persistent  AF Characterize  results 
along the AF  disease 
continuum   
0 
 
 
 
6.0  
 
 
1.2, 5.3, 6.9,  12.1,  
12.4.6  Randomization will occur in  a 
1:1 ratio which decreased  the 
sample size to 70 subjects  and 
upper enrollment limit to  245 
subjects. This  adjustment 
decreased the total  study 
duration.  Primary reason for  2:1 
randomization was  to 
collect additional  safety 
data but strong  safety 
results from  the 
Symplicity HTN -3 study 
lowered the safety  risk 
level  
 
 
0 
 
 
 
6.0  
 
 
3.0, 6.13,  6.15,  
6.17, 6.18, 6.22,  9  
 
Included the Reveal  LINQ 
device which replaced  trans - 
telephonic monitors and  holters 
for recurrent AF  detection.  Reveal LINQ has  been 
commercially  launched 
in the United  States, 
allows unique 
opportunity  to 
continuously monitor  for 
recurrent AF and  collect 
AF burden   
 
 
0 
 
 
 
6.0  
 
3.1, 5.2.2,  6.10,  
6.12 Added the Symplicity  Spyral 
catheter and Symplicity  G3 
Generator. The  Symplicity 
catheter remains in the CIP as  a 
backup catheter for  unforeseen 
circumstances with  Symplicity 
Spyral or  generator.   
Technology 
improvements with  the 
next generation 
catheter   
 
 
0 
6.0 4 Elaborated on what is part  of 
regulatory  compliance  Clarification  0 
6.0 5.2.1  Added inclusion criteria  for 
home  monitoring  New information  0 
6.0 5.2.2  Clarified that subjects may  have 
one repeat  TEE.  Clarification  0 
6.0 5.2.2  Removed loop recorders  from 
exclusion  criteria.  Removed  because 
Reveal LINQ is  allowed  0 
6.0 6.2, 16.1,  16.3 Added Financial  Disclosure 
requirement  Clarification  0 
 
6.0  
6.6 Clarified that dose,  units, 
frequency is only required  for 
anti-hypertensive  medications   
Clarification   
0 
 
 
 
6.0  
 
 
6.7 Added a CT scan to screen  for 
renal anatomy eligibility  followed 
directly by randomization  rather 
than screening for  renal 
anatomy directly after  the 
pulmonary vein  isolation 
procedure.   
Allows for  more 
efficiency with  planning 
of the renal  denervation 
procedure.   
 
 
0 
 
 
 
 
 
 
 
 
 
 
 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 82 of 92 
8179    
Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
 
 
 
 
 
 
 
6.0  
 
 
 
 
 
 
6.7, 6.17,  12.6 Changed trans -thoracic 
echocardiogram  measurement 
to only left atrial volume  index 
for subjects  diagnosed 
persistent  AF. 
 
 
 
 
 
The repeat  trans -thoracic 
echocardiogram at 6  months 
was removed  Want to exclude 
subjects who are  very 
far along the AF 
disease continuum  so 
that the two  groups, 
paroxysmal and 
persistent aren’t  too 
dissimilar  
 
 
Likelihood of seeing  a 
meaningful  difference 
six months  post 
procedure did  not 
warrant this  objective   
 
 
 
 
 
 
0 
 
 
6.0  
 
6.7, 6.17,  12.6  
Removed quality of  life 
questionnaire  Likelihood of seeing  a 
meaningful  difference 
six months  post 
procedure did  not 
warrant this  objective   
 
0 
 
6.0  
5.2.1, 6.7,  6.17,  
12.6 Removed ambulatory  blood 
pressure monitoring  requirement 
and follow up  visit 
measurements  Deemed not critical  for 
this study based  on 
HTN-3 results   
0 
 
6.0  
6.14 Changed the definition of  device 
deficiency   
New information   
0 
 
 
 
 
6.0  
 
 
 
6.17  
 
 
 
Removed the 3 month follow  up 
visit Primary reason for the  3 
month follow up  visit 
was to address  any 
potential safety  issues 
with the renal  artery 
denervation  procedure, 
risk level has  been 
lowered with  recent 
results from  the 
Symplicity HTN -3 study   
 
 
 
0 
 
6.0  
6.18 Included System  Modification 
instructions for the Reveal  LINQ 
device   
New information   
0 
6.0 6.20 Clarified criteria for  permissible 
retreatments  Unnecessary  restriction 
in this feasibility  study  0 
 
6.0  
7 Added instructions for  device 
disposition with the Arctic  Front 
Advance  catheter  Result of including  the 
persistent  AF 
population in the  study   
0 
 
 
6.0  
 
9 Clarified that only  system 
related, procedure  related, 
cardiovascular related  and 
serious AEs will be  collected 
rather than all  AEs Safety risk level  has 
been lowered  with 
recent results from  the 
Symplicity HTN -3 study   
 
0 
 
6.0  
9 Changed Adverse Events 
Adjudication Committee  (AEAC) 
to Clinical Events  Committee 
(CEC)  Clarification  because 
the committee  will 
review more  than 
adverse  events   
0 
6.0 9.1 Added chest pain to  the 
unavoidable AE  table  Reasonable  expectation 
of occurrence  0 
 
 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 83 of 92 
8179    
Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
6.0 9.3 Elaborated  market -release 
reporting  requirements  Clarification  0 
6.0 10 Added risks associated with  the 
Reveal LINQ  device  New information  0 
 
6.0  
12.3.4  Updated performance  criteria 
with recent Symplicity  HTN-3 
study  results  New information  from 
the Symplicity  HTN-3 
study   
0 
 
6.0  
12.4 Updated primary  effectiveness 
objective because of how  events 
are collected with the  Reveal 
LINQ  device  Continuous AF 
detection which  wasn’t 
possible with  Holter 
and TTM  
0 
 
6.0  
12.6  
Added AF burden to  ancillary 
objectives  Reveal LINQ  calculates 
daily AF burden  which 
is of interest in  this 
patient  population   
0 
 
 
6.0  
 
12.6  
Removed freedom from  atrial 
tachyarrhythmias  ancillary 
objective  Reveal LINQ does  not 
have the capability  to 
discriminate all  atrial 
arrhythmias  without 
making tradeoffs on  AF 
collection   
 
0 
 
6.0  
12.7  
Added subgroup  analysis  A result of  including 
persistent AF patients  in 
the study   
0 
 
6.0  
Appendix  E Included institutions and  IRBs 
that are expected to  participate 
in the  study   
New information   
0 
 
 
6.0  
 
Appendix  F Clarified that  commercially 
released Arctic Front  Advance 
Cryoablation Systems will  be 
used in the study and  not 
relabeled as  investigational   
 
Clarification   
 
0 
 
 
7.0  
 
3.0 and  throughout   
Removed reference to the  first 
generation Symplicity  catheter 
and RF  Generator  Only the  next 
generation  Symplicity 
Spyral catheter  and 
Symplicity  G3 
Generator will be  used 
in the  study   
 
11 
7.0 9.1 Removed chest pain  from 
unavoidable  AEs Per FDA 
recommendation  11 
 
7.0  
12.7 Subgroup analysis group  added 
for those who receive touch  up 
RF vs.  not. Per FDA 
recommendation   
11 
 
8.0  
Throughout   
Added Arctic Front Advance  ST This device is  approved 
for use in the  United 
States   
0 
8.0 3.3 Added one sentence  regarding 
the AF detection  algorithm  Clarification  0 
 
8.0  
6.4 Added Role of the  sponsor 
representative during  study 
procedures and follow up  visits   
Clarification   
0 
 
 
 
 
 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 84 of 92 
8179    
Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
 
8.0  
6.7  
Removed outdated reference  to 
a 3-month  visit Correction. Missed  on 
prior revision when  the 
3-month  visit was 
removed.   
0 
8.0 6.14 Subjects with existing  Reveal 
LINQ devices may be  enrolled  Clarification  0 
 
8.0  
6.17 Changed the visit  window 
calculation to date of  pulmonary 
vein isolation  procedure   
Clarification   
0 
 
8.0  
10  
Added two  risks Known risks reported  in 
literature and  field 
performance  data  
0 
 
8.0  
12.4 Added language stating  the 
primary effectiveness  objective 
analysis includes AF  detected 
from Reveal  LINQ   
Clarification   
0 
8.0 Appendix  E Updated center  information  New information  0 
9.0 Throughout  Removed Arctic Front  Advance 
ST Business  decision  0 
 
9.0  
6.23 Removed alternative sources  to 
document AF  recurrence.  Reveal LINQ is the  only 
source for recurrent  AF 
allowed per  protocol   
0 
 
9.0  
12.4 Removed ECG and Holter  as 
contributing to the definition  of 
treatment failure for  document 
AF recurrence.  Reveal LINQ is the  only 
source for recurrent  AF 
allowed per  protocol   
0 
10.0 1.2 Updated study  duration  New information  Not applicable  
 
 
10.0  
 
5.2.1 and  6.8  
Inclusion criteria for  blood 
pressure was  lowered  Supports a larger  cohort 
of patients  who 
continue  to have 
increased  sympathetic 
tone  
 
Not applicable  
 
 
10.0  
 
5.2.1 and  6.7  
Inclusion criteria for number  of 
antihypertension  medications 
was lowered  Supports a larger  cohort 
of patients who  have 
uncontrolled 
hypertension on  one 
antihypertensive 
medication   
 
Not applicable  
 
 
 
10.0  
 
 
5.2.1 and  6.7  
 
Inclusion criteria  for 
hypertension medication  at 
maximum dose was  removed  Supports a larger  cohort 
of patients who are  not 
on maximum 
antihypertensive 
medication dose:  avoids 
medication  adherence 
identified in this 
population   
 
 
Not applicable  
 
 
 
10.0  
 
 
5.2.2  Removed exclusion criteria for  a 
condition where manipulation  of 
the catheter within the  heart 
would be unsafe but retained  the 
evaluation as a requirement  to 
occur prior to the  ablation 
procedure.   
Generally not  assessed 
at the Baseline  exam 
because the  ablation 
procedure date has  not 
been  scheduled   
 
 
Not applicable  
10.0 6.7 Removed discouragement  to 
enroll subjects on  amiodarone.  Changed because  of 
enrollment  barrier  Not applicable  
 
 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 85 of 92 
8179    
Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
 
10.0  
6.9 Removed the word sealed  from 
the randomization  envelops, 
envelops have a blinded  code 
label.   
Clarification   
Not applicable  
 
10.0  
6.15 Added “labeling” to the end  of 
the sentences starting  with 
NOTE.  Inadvertently missed  so 
complete text  was 
added   
Not applicable  
 
 
10.0  
 
9.3 Added “impairment to a  body 
structure or a body function”  to 
the bullet point that begins  with 
A condition  necessitating 
medical or surgical  intervention 
to prevent  permanent   
Inadvertently missed  so 
complete text  was 
added   
 
Not applicable  
 
10.0  
9.5.1  Reworded the first paragraph  to 
align with the CRF name  and 
noted that’s it should be a  SAE 
that led to  death.   
Clarification   
Not applicable  
 
10.0  
9.5.2  In the Unknown  Cardiac 
Classification,  corrected 
sufficient to  insufficient   
Typo   
Not applicable  
 
10.0  
10 Added lung lesion  and 
Gastroparesis  Known risks reported  in 
literature and  field 
performance  data  
New information  
 
10.0  
12.4.4  Changed day zero to date  of 
procedure, not dated  of 
randomization and  revised 
assessment of time to  event.   
Clarification   
Not applicable  
10.0 Appendix  C A DMC charter has been  written  New information  Not applicable  
10.0 Appendix  E Updated center  information  New information  Not applicable  
 
 
 
 
11.0  
 
 
 
5.2.1  The inclusion criteria for  blood 
pressure and  antihypertensive 
medications was modified  to 
include: subjects  whose 
antihypertensive drug regimen  is 
not expected to change for  at 
least 6 months, as  determined 
by their referring  cardiologist 
and/or the  investigator   
Safety consideration  for 
those subjects  with 
uncontrolled 
hypertension during  the 
first 6 months  post 
procedure   
 
 
 
Not applicable  
11.0 6.7 Included the requirement  to 
collect medication  purpose  Inadvertently  removed 
during prior  revisions  Not applicable  
 
 
 
11.0  
 
 
6.8 Subjects with an average of  3 
systolic blood  pressure 
measurements ≤ 140  mmHg 
may have a repeat  blood 
pressure assessment. The  last 
version of this CIP  stated  
>140mmHg.   
 
 
Typo   
 
 
Not applicable  
 
 
 
11.0  
 
 
6.8 The TEE section was  reworded 
to state: “Subjects noted to  have 
left atrial thrombus on TEE  will 
not undergo the procedure  and 
will be exited from the  study 
unless thrombus resolution  is 
confirmed on a repeat  TEE.”   
 
 
Clarification   
 
 
Not applicable  
 
 
 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 86 of 92 
8179    
Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
 
 
 
 
 
 
12.0  
 
 
 
 
 
5.2.1  The inclusion criteria for  blood 
pressure and  antihypertensive 
medications was modified  to 
include: The subject should  be 
on a stable  antihypertensive 
drug regimen with no  changes 
for a minimum of 2 weeks  prior 
to enrollment and  the 
antihypertensive drug regimen  is 
not expected to change for  at 
least 6 months, as  determined 
by the subject’s  referring 
cardiologist and/or  the 
investigator.   
 
 
 
 
 
Clarification   
 
 
 
 
 
17 
13.0 Title Page / Table 1  Added European contacts  European expansion  Not applicable  
13.0 Table 2  Added core lab information  New Information  Not applicable  
13.0 Section 1  Added European device/study 
status information and 
expansion of 3 sites  Include additional 
European centers to aid 
enrollment rate  Not applicable  
13.0 Section 1.2  Increased center randomization 
cap from 30% to 50%  Allow high enrolling sites 
to continue enrollment to 
meet overall enrollment 
target  Not applicable  
13.0 Section 3  Added European information for 
system description and intended 
use European expansion  Not applicable  
13.0 Section 3.4  Added Achieve AdvanceTM as 
an additional system component  Newly approved device 
available for use  Not applicable  
13.0 Section 4  Added European regulatory 
compliance information  European expansion  Not applicable  
13.0 Section 4  Added explanation of 
requirements for revisions to the 
CIP Clarification  Not applicable  
13.0 Table 5  Switched order of CT Scan and 
Cryoablation Procedure to 
chronological order  Typo  Not applicable  
13.0 Section 6.2  Added European center 
activation requirements  European expansion  Not applicable  
13.0 Section 6.6  Added European patient 
informed consent process 
requirements  European expansion  Not applicable  
13.0 Section 6.12  Removed statement “If the 
angiogram confirms anatomy 
eligibility, the subject will be 
randomized”  Typo - subject is 
randomized after CT 
scan  Not applicable  
13.0 Section 6.17  Added additional follow up visit 
windows in Table 6  Study length increase  Not applicable  
13.0 Section 7  Added European requirements 
for device storage, handling and 
traceability  European expansion  Not applicable  
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 87 of 92 
8179   Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
13.0 Section 8  Added note that study 
deviations are not required if a 
subject misses a monthly LINQ 
manual interrogation  Nightly automatic 
transmissions can be 
reviewed for AF 
episodes  Not applicable  
13.0 Section 9  Added European adverse event 
and device deficiency 
requirements  European expansion  Not applicable  
13.0 Section 12  Added: subjects who are 
randomized to the treatment 
group and are found not to meet 
inclusion/exclusion criteria 
during the renal denervation 
procedure will not count toward 
the 70 subjects randomized and 
will be included in a modified 
intention -to-treat analysis  Clarification  Not applicable  
13.0 Section 12.9  Added a section regarding 
method for pooling of study 
centers for analysis  Clarification  Not applicable  
13.0 Section 14  Added insurance information  Clarification  Not applicable  
13.0 Section 16  Added European requirements 
for required records and reports  European expansion  Not applicable  
13.0 Appendix E  Participating investigators, 
institutions and IRB/MECs 
updated to current status  New Information  Not applicable  
13.0 Appendix F  Added European labeling 
information  European expansion  Not applicable  
13.0 Throughout  Added reference to medical 
ethics committee (MEC) and 
regulatory bodies throughout  European expansion  Not applicable  
14.0 Throughout  Sponsor internal distribution 
only Sponsor  internal  
discussion  Not applicable  
15.0 Table 1  Revised Study sponsors and 
contacts  Updated information  47 
15.0 Section 5.2 .2 Removed exclusion criteria for 
pacemakers and defibrillators  Supports a larger cohort 
of patients contributing 
to enrollment  47 
15.0 Section 5.2 .2 and 
6.12 Added the maximum renal 
artery diameter acceptable for 
the exclusion criteria  Typo  47 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 88 of 92 
8179   Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
15.0 Section 6.5 and 
6.18.2  Allow a CareLink transmission 
from the subject’s home as a 
substitution for an in -office 
device interrogation  Clarification  47 
15.0 Section 7.1 and 7.3  Changed pedal to switch  Typo  47 
15.0 Section 7.2, Table 7 
and Appendix F  Added Freezor MAX  Clarification  47 
15.0 Section 10  Modified risks to align with the 
current Arctic Front Advance 
IFU and added that the current 
Arctic Front Advance IFU should 
be referenced with respect to 
the possible risks  Updated to reflect 
recently approved 
labeling for the 
commercialized device  47 
15.0 Section 12.3  Added text to the Safety 
Composite Event definition  Clinical Events 
Committee c larification  
request  47 
15.0 Appendix E  Participating investigators, 
institutions and IRB/MECs 
updated to current status  New Information  47 
16.0 Table 1  Revised Study sponsors and 
contacts  Updated information  55 
16.0 Table 2  Revised Study Core Labs  Updated information  55 
16.0 Table 3  Revised Committee contact 
information  Clarification  of Steering 
Committee  55 
16.0 Section 1.2  Revised Study description  Updated expected total 
study duration and 
months of enrollment 
given time needed to 
reach required  subject  
treatment numbers  55 
16.0 Section 1.2  Revised Study description  Updated to include 
provisions for the 
conduct of interim 
analyses  55 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 89 of 92 
8179   Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
16.0 Section 2  Revised section to include 
recently published renal 
denervation study results  New information  55 
16.0 Section 2  Included use of Arctic Front 
Advance Pro Cardiac 
Cryoablation Catheter  AFA Pro recently 
granted FDA approval  
and CE mark  55 
16.0 Table 4  Added Model Number (s) for 
AFA Pro Cardiac Cryoablation 
Catheter  AFA Pro recently 
granted FDA approval  
and CE mark  55 
16.0 Section 3.2  Included use of Arctic Front 
Advance Pro Cardiac 
Cryoablation Catheter  AFA Pro recently 
granted FDA approval  
and CE mark  55 
16.0 Section 5.2.2  Reinstated prior exclusion 
criteria for pacemakers and 
defibrillators  Protocol required LINQ 
monitoring for recurrent 
AF is not recommended  
in subjects with 
implantable Medtronic 
pacemakers and 
defibrillators ; CareLink 
monitor unable to  
distinguish specific 
device  for pairing ; to 
ensure all recurrent AF 
in this study is capt ured 
via LINQ , implanted 
pacemakers and 
defibrillators  from 
varying manufacturers  
will not be allowed  55 
16.0 Section 6.1  Included use of Arctic Front 
Advance Pro Cardiac 
Cryoablation Catheter  AFA Pro recently 
granted FDA approval  
and CE mark  55 
16.0 Section 6.10  Included use of Arctic Front 
Advance Pro Cardiac 
Cryoablation Catheter  AFA Pro recently 
granted FDA approval 
and CE mark  55 
16.0 Section 6.24  Revised Study exit to allow for 
exit of subject with Reveal LINQ 
battery reaching end of life after 
completing at least 6 months of 
study follow -up Support study subject 
safety  and study 
participation satisfaction  
by not requiring repeat 
LINQ implant when 
study objective data is 
available and additional 
implant not clinically 
warranted  55 
16.0 Section 7.2  and 
Table 7  Included use of Arctic Front 
Advance Pro Cardiac 
Cryoablation Catheter  AFA Pro recently 
granted FDA approval  
and CE mark  55 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 90 of 92 
8179   Version  Applicable 
Sections  Change  Rationale  Number  of 
subject  enrolled  
16.0 Section 12.1  Added clarification for objective 
analyses and timepoints for 
potential interim analyses  Clarification and new 
information  55 
16.0 Section 12.4.6  Revised power and sample size 
calculation assumptions  Provide new information 
resulting from provisions 
to conduct potential 
interim analyses  55 
16.0 Section 12.8  Included the c onduct of interim 
analyses  Aid sponsor decisions 
for continuing study  55 
16.0 Section 12.8  Table added to show timepoints 
at which interim analyses may 
be conducted  Provide information 
regarding the pass/fail of 
primary effectiveness 
objectives for each 
scenario  55 
16.0 Section 12.8  Added clarification of DMC’s 
role in reviewing effectiveness 
data Revised to reflect the 
conduct of interim 
analyses and the  review 
of effective ness data by 
the DMC  55 
16.0 Appendix C  Added clarification of DMC’s 
role in reviewing effectiveness 
data Revised to reflect DMC 
review of effectiveness 
data generated by the 
conduct of interim 
analyses  55 
16.0 Appendix E;  
Table 14  Participating investigators, 
institutions and IRB/MECs 
updated to current status  New information  55 
16.0 Appendix F  Included use of Arctic Front 
Advance Pro Cardiac 
Cryoablation Catheter  AFA Pro recently 
granted FDA approval  
and CE mark  55 
17.0 Section 6.18 Added alternate Follow -up 
methods  To allow for  extenuating 
circumstances, such as 
a global pandemic.  98 
17.0 Table 1  Updated  Study sponsors and 
contacts  Updated information  98 
17.0 Section 3  Added MyCareLink Patient 
Monitor  Model number  24952  24952 Model number is 
available on the market 
in Europe  98 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 91 of 92 
8179   17.0 Throughout 
Document  Minor administrative and 
formatting updates  Updated information  98 
17.0 Throughout 
Document  Updated based on received 
FDA approval of Arctic Front 
Advance, Arctic Front Pro and 
Freezor MAX with the Persistent 
AF expanded indication for the 
treatment of drug refractory 
recurrent symptomatic 
paroxysmal and persistent atrial 
fibrillation (episode duration less 
than 6 months)  Updated information  98 
17.0 APPENDIX E:  Removed PARTICIPATING 
INVESTIGATORS, 
INSTITUTIONS AND IRB/MECS  
list  
 A complete list of 
participating 
investigators, institutions 
and IRB/MECs where 
study activities will be 
conducted will be 
distributed under a 
separate cover  
 98 
18.0 Section 6.18 Administrative update to remove 
the following sentence from the 
section 6.18.  “Scheduled in -
office follow -up visits” . These 
alternative methods have no 
potential impact on patient 
safety, do not affect data 
integrity and do not introduce 
study bias.’  Thi s sentence was 
added in version 17.0 of the CIP 
which was not implemented 
prior to version 18.0. Per recommendation 
from FDA  100 
 
 
 
1 Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US  adult  population: 
results from the Third National Health and Nutrition Examination Survey,  1988 - 1991. 
Hypertension 1995; 25: 305 -313. 
2 Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis,  and 
predisposing conditions for atrial fibrillation: population -based estimates. Am J  Cardiol  
1998; 82(suppl):  2-9. 
3 Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic  atrial  
fibrillation: the Framingham study. N Engl J Med 1982; 306:  1018 -1022.  
4 Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk  factor  for 
complications, and potential therapeutic target. Am J Cardiol 2003; 91(suppl):  9-14. 
5 Aksnes TA, Kjeldsen SE. A link between hypertension and atrial fibrillation: methods  of 
treatment and prevention. Curren t Vascular Pharmacology 2010; 8:  769-774. 
Version 18 19AUG 2020  Symplicity AF 
Clinical Investigation Plan 
Medtronic  Confidential Page 92 of 92 
8179   6 Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation:  incidence,  risk 
factors, and prognosis in the Manitoba Follow -Up Study.  Am J Med 1995; 98:  476-484.  
7 Psaty BM, Manolio TA, Kuller LH, et al.  Incidence of and risk factors for atrial  fibrillation  in older 
adults. Circulation 1997; 96:  2455 -2461.  
8 Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the predictive parameters  for the 
onset of atrial fibrillation in patients with essential hypertension. Am Heart J 2000;  139: 814-819. 
9 Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces  new-onset  atrial 
fibrillation and subsequent stroke compared to atenolol: the Losartan Inter vention  for End point 
Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:  712-719. 
10 Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of  atrial  fibrillation  in 
patients  with heart  failure:  results  from the  Valsartan  Heart  Failure  Trial (Val- HeFT). Am Heart 
J 2005; 149:  548-557. 
11 Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of  atrial  
fibrillation in patients with left ventricular dysfunction: insight from the Studies of  Left 
Ventricular Dysfunction (SOLVD) Trials. Circulation 2003; 107:  2926 -2931.  
12 Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation  with angiotensin -
converting enzyme inhibitors and angiotensin receptor blockers:a  meta - analysis. J Am 
Coll Cardiol  2005;45:1832 -1839.  
13 Shi Y, Li D, Tardif JC, et al. Enalapril effects on atrial remodeling and atrial fibrillation  in 
experimental congestive heart failure. Cardiovasc Res 2002; 54:  456-461. 
14 Townsend, R.R., et al., Catheter -based renal denervati on in patients with uncontrolled 
hypertension in the absence of antihypertensive medications (SPYRAL HTN -OFF MED): a 
randomised, sham -controlled, proof -of-concept trial. The Lancet, 2017. Published online 
August 28, 2017 http://dx.doi.org/10.1016/S0140 -6736(17)32281 -X 
15 Kandzari, D.E., et al., Effect of renal denervation on blood pressure in the presence of 
antihypertensive drugs: 6 -month efficacy and safety resul ts from the SPYRAL HTN -ON MED 
proof -of-concept randomised trial. The Lancet, 2018. Published online May 23, 2018 
http://dx.doi.org/10.1016/S0140 -6736(18)30951 -6 
16 Pokushalov E, Romanov A, Corbuc ci G, et al. A randomized comparison of  pulmonary  vein 
isolation with versus without concomitant renal artery denervation in patients  with refractory 
symptomatic atrial fibrillation and resistant hypertension.  J Am Coll  Cardiol  2012; 60:  1163 -
1170.  
17 Calkins, H., et al., HRS/EHRA/ECAS expert Consensus Statement on catheter  and surgical 
ablation of atrial fibrillation: recommendations for Patient selection,  procedural  techniques and 
follow -up, definitions, endpoints and research trial design. A report o f the Heart Rhythm Society 
(HRS) Task Force on catheter and surgical ablation of  atrial  fibrillation. Heart Rhythm, 2012; 9(4): 
p. 632-696.e20.  
18 Mancia G. Blood pressure reduction and cardiovascular outcomes: Past, present,  and future. 
Am K Cardiol.  2007;100:3J -9J. 
19 Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking,  and death 
from coronary heart disease. Overall findings and differences by age for  316,099  white men. 
Multiple risk factor intervention trial research gr oup. Archives of  internal  medicine.  
1992;152:56 -64. 
20 Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Cooper  J, Ekborn T, 
Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risks of untreated  and treated 
isolated systolic hypertension in the elderly: Meta -analysis of outcome  trials.  
Lancet. 2000;  355:865 -872. 